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Abstract
The Panel on Food additives and Flavourings of the EFSA was requested to update Flavouring Group
Evaluation 13 using the Procedure as outlined in Commission Regulation (EC) No 1565/2000, to
include an evaluation of the flavouring substances 2-ethyl-5-methylfuran [FL-no: 13.125] and 2-
octylfuran [FL-no: 13.162]. FGE.13 revision 3 (FGE.13Rev3) deals with 26 flavourings substances of
which 24 have been already evaluated to be of no safety concern. For [FL-no: 13.125] and [FL-no:
13.162], a concern for genotoxicity was raised in FGE.13Rev1. This concern could be ruled out based
on new genotoxicity data on supporting substances in FGE.67Rev3. Subsequently, [FL-no: 13.125 and
13.162] were evaluated, through a stepwise approach that integrates intake from current uses,
toxicological threshold of concern (TTC), and available data on metabolism and toxicity, along the B-
side of the Procedure, making use of a BMDL of 8.51 mg/kg body weight (bw) per day. The
Panel derived this BMDL from an oral subchronic toxicity study with the supporting substance 2-
pentylfuran [FL-no: 13.059]. Using this BMDL, for [FL-no: 13.125 and 13.162], adequate margins of
safety were calculated based on the MSDI approach. The Panel concluded that the 26 candidate
substances in FGE.13Rev3 do not give rise to safety concerns at their levels of dietary intake, when
estimated on the basis of the MSDI approach. Adequate specifications for the materials of commerce
have been provided for all 26 substances. Data on uses and use levels are needed for [FL-no: 13.130].
For 21 flavouring substances [FL-no: 13.011, 13.102, 13.108, 13.113, 13.114, 13.122, 13.125, 13.127,
13.129, 13.132, 13.133, 13.135, 13.136, 13.139, 13.141, 13.143, 13.146, 13.149, 13.162, 13.178 and
13.185], the mTAMDI intake estimates are above the TTC for their structural class and more reliable
data on uses and use levels are required to finalise their evaluation.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
1.1.1. Background
The use of flavourings is regulated under Regulation (EC) No 1334/2008 of the European
Parliament and Council of 16 December 20081 on flavourings and certain food ingredients with
flavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an
evaluation and approval are required for flavouring substances.
The Union list of flavourings and source materials was established by Commission Implementing
Regulation (EC) No 872/2012.2 The list contains flavouring substances for which the scientific
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000.3
1. FGE.67Rev1
On 6 July 2011, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing
Aids (CEF) adopted an opinion on Flavouring Group Evaluation 67, Revision 1 (FGE.67Rev.1):
Consideration of 40 furan-substituted aliphatic hydrocarbons, alcohols, aldehydes, ketones, carboxylic
acids and related esters, sulfides, disulfides and ethers evaluated by JECFA at the 65th meeting
(JECFA, 2006b) and re-evaluated at the 69th meeting (JECFA, 2009c).4
In its opinion, the Panel concluded that for the substances [FL-no: 13.059, 13.069, 13.103, 13.106
and 13.148] additional toxicity/genotoxicity data are required.
2. FGE.13Rev2
On 6 July 2011, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing
Aids (CEF) adopted an opinion on Flavouring Group Evaluation 13, Revision 2 (FGE.13Rev2): Furfuryl
and furan derivatives with and without additional side-chain substituents and heteroatoms from
chemical group 14.5
In its opinion the Panel stated that it has reservations for the substances [FL-no: 13.125 and
13.162] which could not be evaluated through the procedure due to concern of genotoxicity in vitro.
For these two substances additional data are required.
On 29 April 2014, the European Flavour Association (EFFA) submitted additional data on
2-pentylfuran [FL-no: 13.059] from FGE.67, which is relevant to the safety assessment of this group of
7 alkylfurans.
1.1.2. Terms of Reference as provided by the requestor
The European Commission requests the European Food Safety Authority (EFSA) to evaluate this
new information and, depending on the outcome, proceed to the full evaluation of these flavouring
substances in accordance with Commission Regulation (EC) No 1565/2000.
1.2. Interpretation of the Terms of Reference
In FGE.67Rev1, the CEF Panel agreed with JECFA that the substances [FL-no: 13.045, 13.054,
13.059, 13.066, 13.069, 13.070, 13.083, 13.101, 13.103, 13.105, 13.106, 13.138, 13.148, 13.163]
cannot be evaluated through the Procedure, based on concerns with respect to genotoxicity. These
substances are structurally related to [FL-no: 13.125 and 13.162] evaluated in FGE.13Rev2 by the CEF
Panel, who identified the same concern for genotoxicity as for the structurally related alkylfurans in
FGE.67Rev2. Therefore, for all substances indicated here for FGE.67Rev2 and FGE.13Rev2, additional
data were required.
1 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and certain
food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91,
Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34–50.
2 Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of flavouring substances provided
for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to Regulation (EC)
No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC) No 1565/2000 and
Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1–161.
3 Commission Regulation (EC) No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8–16.
4 EFSA Journal 2011;9(10):2315.
5 EFSA Journal 2011;9(8):2313.
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Industry has submitted data on the representative substances 2-pentylfuran [FL-no: 13.059] and 2-
acetylfuran [FL-no: 13.054]. Data on 2-pentylfuran [FL-no: 13.059] are also applicable for the
candidate substances [FL-no: 13.125 and 13.162] in FGE.13Rev3 since these are structurally related.
Based on new toxicity data on supporting substances in FGE.67Rev3, the European Commission
requests EFSA to carry out a safety assessment on the substances 2-ethyl-5-methylfuran [FL-no:
13.125] and 2-octylfuran [FL-no: 13.162] in accordance with Commission Regulation (EC) No 1565/
20003. The rest of the substances covered by the current mandate [FL-no: 13.045, 13.054, 13.059,
13.066, 13.069, 13.070, 13.083, 13.101, 13.103, 13.105, 13.106, 13.138, 13.148 and 13.163] will be
considered in FGE.67Rev3.
1.3. History of the evaluation of the substances in FGE.13
The flavouring group evaluation 13 (EFSA, 2005) included 18 flavouring substances from chemical
group 14 (Annex I of Commission Regulation (EC) No 1565/20003). All the candidate substances are
furan derivatives and can be divided into two subgroups, depending on the absence/presence of
sulfur-containing substituents.
The nine candidate substances in subgroup 1 are furfuryl alcohol derivatives such as esters of
furfuryl alcohol [FL-no: 13.127, 13.129, 13.132, and 13.133] or furanacrylic acid [FL-no: 13.011], furoic
acid [FL-no: 13.136] and its esters [FL-no: 13.102 and 13.122] and 5-hydroxymethylfurfuraldehyde
[FL-no: 13.139].
The nine candidate substances of subgroup 2 are all sulfur-containing furan derivatives. The sulfur
is present in the molecule as a free thiol group [FL-no: 13.108 and 13.149], as thioethers [FL-no:
13.114, 13.145 and 13.124], as disulfides [FL-no: 13.113, 13.144 and 13.178] or as trisulfide [FL-no:
13.146].
The 18 candidate substances are closely structurally related to 47 flavouring substances (supporting
substances) evaluated at the 55th and 59th JECFA meetings (JECFA, 2001a,b, 2002, 2003) in the
groups of ‘Furfuryl alcohol and related substances’ and ‘sulfur substituted Furan derivatives’.
The AFC Panel considered that except for the flavouring substance 5-hydroxymethylfurfuraldehyde
[FL-no: 13.139], the in vitro and in vivo data available did not give rise to concern with respect to
genotoxicity of the remaining eight flavouring substances included in subgroup 1. Accordingly, the AFC
Panel applied the Procedure (B-side) to eight substances and indicated that the Procedure cannot be
applied to [FL-no: 13.139], pending submission of in vivo genotoxicity data.
Considering that the seven candidate substances of subgroup 1 (non-sulfur-containing) are
metabolised to yield furfural and furoic acid, the toxicity of the esters of furfuryl alcohol [FL-no:
13.127, 13.129, 13.132 and 13.133], furoic acid [FL-no: 13.102 and 13.122] and furanacrylic acid [FL-
no: 13.011] is expected to be similar to that of the structurally related supporting substance furfural
[FL-no: 13.018] and of the candidate substance 2-furoic acid [FL-no: 13.136], which is the major
metabolite of furfural. For furfural [FL-no: 13.018], the AFC Panel (EFSA, 2004b) established an
acceptable daily intake (ADI) value of 0.5 mg/kg bw based on an NOAEL (no observed adverse effect
level) for hepatotoxicity in a 90-day toxicity study in rats of 54 mg/kg bw per day to which a safety
factor of 100 was applied. The estimated daily per capita intakes based on the MSDI approach of
candidate substances in subgroup 1 were more than 500-fold below the ADI value.
Since no toxicity data were available on the nine sulfur-containing candidate substances in
subgroup 2, the relevant NOAEL values were derived from structurally related supporting substances.
The AFC Panel concluded at step B4 of the Procedure that 17 candidate substances included in
FGE.13 pose no safety concern when they are used as flavouring substances at the estimated levels of
intake based on the MSDI approach.
The AFC Panel considered that for 10 of the 17 flavouring substances taken through the Procedure,
the intakes, estimated on the basis of the mTAMDI, exceeded the relevant threshold for their structural
class, to which the flavouring substance was assigned. Therefore, for these 10 substances, more
reliable exposure data were required.
The AFC Panel requested information on geometrical isomerism/chirality for the substances [FL-no:
13.011, 13.127 and 13.129].
The first revision of FGE.13, FGE.13Rev1, included the assessment of seven additional candidate
substances [FL-no: 13.125, 13.135, 13.141, 13.143, 13.162, 13.185 and 13.199]. Therefore, 25
substances were evaluated in FGE.13Rev1 (EFSA CEF Panel, 2010).
The evaluation of the flavouring substance 2,5-dimethyl-3-(methyldithio)furan [FL-no: 13.113] was
revised because a supporting substance [FL-no: 13.055] was identified with better structural similarity
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to [FL-no: 13.113] than the one that was used in FGE.13. This new supporting substance would
provide a better basis for the assessment of [FL-no: 13.113] and with its NOAEL of 5 mg/kg bw per
day, an adequate margin of safety was calculated for [FL-no: 13.113].
For 12 flavouring substances already considered in FGE.13, the classification according to Cramer
et al., 1978 was revised. These revisions were necessary to create consistency with the evaluations in
FGEs 65 and 67. For the substances involved, the final conclusions were not changed.
In addition, the CEF Panel noted that the substance [FL-no: 13.178] is synonymous with [FL-no:
13.192],6 which was evaluated by the JECFA (JECFA no 1542) at its 69th meeting (JECFA, 2009a). For
this substance in the JECFA evaluation, an MSDI for Europe of 0.24 lg per capita per day was given.
This figure, which is higher and more recent than the exposure estimate in FGE.13 (0.0012 lg per
capita per day), was used in FGE.13Rev1.
Based on data on the genotoxic activity of 5-hydroxymethylfurfural [FL-no: 13.139] there was
sufficient evidence for a genotoxic potential in vitro, which could not be ruled out, due to a lack of
genotoxicity data in vivo. Therefore, [FL-no: 13.139] was not evaluated through the Procedure. For the
remaining substances in subgroup Ia, the data available did not indicate a concern for genotoxicity and
these were evaluated through the Procedure.
For the two candidate substances in subgroup Ib [FL-no: 13.125 and 13.162], metabolism studies
on closely related substances indicated a potential for DNA binding of metabolites. In addition, in
several in vitro studies with structurally related substances, indications for genotoxic activity were
obtained. These data precluded the evaluation of [FL-no: 13.125 and 13.162], through the Procedure.
There is an absence of data on genotoxicity for 14 sulfur-containing candidate substances included
in main group II, or on the related supporting substances. Nevertheless, this did not preclude the
evaluation of these substances through the Procedure.
No toxicity data were available on the sulfur-containing furan-derived candidate substances
included in main group II. However, results from toxicity studies on 14 structurally related supporting
substances and one related substance have been reported. Many of the available studies were
performed either with a single dose level or multiple dose levels that produced no effects; the doses
producing no adverse effects ranged from 0.45 to 10 mg/kg per day, and based on this information for
each of the 14 substances in group II, an adequate margin of safety (MOS) was calculated at step B4
of the Procedure. For one substance [FL-no: 13.114], the evaluation at step B4 was better described in
FGE.13Rev1, since this had not been made explicit in FGE.13.
For 18 of the candidate substances, evaluated using the Procedure, the mTAMDI was above the
threshold of concern; therefore, the CEF Panel indicated that more reliable intake data were needed.
The CEF Panel had reservations for [FL-no: 13.185 and 13.199] (missing data on stereoisomerism)
and for [FL-no: 13.125, 13.139 and 13.162] which could not be evaluated through the Procedure due
to concern of genotoxicity in vitro. For these five substances, additional data were required. For the
remaining 20 substances [FL-no: 13.011, 13.102, 13.108, 13.113, 13.114, 13.122, 13.124, 13.127,
13.129 13.132, 13.133, 13.135, 13.136, 13.141, 13.143, 13.144, 13.145, 13.146, 13.149 and 13.178],
the CEF Panel concluded that they would be of ‘No safety concern at estimated levels of intake as
flavouring substances’ based on the MSDI approach.
In FGE.13Rev2, two flavouring substances were added: furfuryl butyrate [FL-no: 13.130] and
2-methyl-5-propionylfuran [FL-no: 13.155]. Therefore, 27 substances were considered in FGE.13Rev2.
For furfuryl butyrate [FL-no: 13.130], JECFA did evaluate the specifications, but did not perform a
safety evaluation. No toxicity or metabolism data and no use levels data were submitted for this
substance.
In FGE.13Rev2, the genotoxicity concern for 5-hydroxymethylfurfural [FL-no: 13.139] was ruled
out, and based on new toxicity data, the substance was evaluated via the Procedure to be of no safety
concern.
New information from industry on the stereoisomeric composition of two candidate substances
[FL-no: 13.185 and 13.199] were also included in FGE.13Rev2.
In FGE.13Rev1, the substance [FL-no: 13.135] (1-(2-furfurylthio)propanone) was incorrectly allocated
to a subgroup of thioesters and evaluated as the thioester S-furfuryl-propanethioate. In FGE.13Rev2, the
candidate substance [FL-no: 13.135] was allocated to and re-evaluated in subgroup IIa, consisting of
6 The substance [FL-no: 13.192] has not been added to the Union List, i.e. Commission Implementing Regulation (EU) No 872/2012
of 1 October 2012 adopting the list of flavouring substances provided for by Regulation (EC) No 2232/96 of the European
Parliament and of the Council, introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the
Council and repealing Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC.
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sulfides. Since there were no further thioester candidate substances left in this FGE, the respective
subgroup was deleted.
One a,b-unsaturated ketone 2-methyl-5-propionylfuran [FL-no: 13.155] and seven supporting
substances (including 2-acetylfuran [FL-no: 13.054]) from FGE.19 subgroup 4.5) were added in a new
subgroup (Ib) of FGE.13Rev2. In the course of the assessment, the CEF Panel concluded that the a, b-
unsaturated structure in conjugation with an aromatic ring system, which is present in these eight
substances as well as in acetophenone, is not considered a structural alert for genotoxicity; therefore,
subgroup 4.5 was not included in the updated list of FGE.19 substances (EFSA, 2008). Nevertheless,
the experimental genotoxicity data indicate that the supporting substance 2-acetylfuran [FL-no:
13.054] may give rise to DNA damage, which may result in chromosomal aberrations rather than gene
mutations. The formation of DNA-reactive metabolites may be anticipated (EFSA CEF Panel, 2011).
The available genotoxicity data are sufficiently strong to raise a concern, which would preclude the
evaluation of the substance [FL-no: 13.155] through the Procedure.
Extensive ring opening with formation of intermediates reactive towards DNA has been reported for
2-alkyl-substituted furans in subgroup Ic that also includes the newly added candidate substances [FL-
no: 13.125 and 13.162]. In addition, these compounds may be metabolised to ketones (as for [FL-no:
13.155] in subgroup Ib), for which genotoxicity may be anticipated.
The CEF Panel had reservations for three substances [FL-no: 13.125, 13.155 and 13.162] which
could not be evaluated through the Procedure due to concern for genotoxicity in vitro. For these three
substances, additional data were required.
Since the last revision of FGE.13 (FGE.13Rev2), industry has withdrawn their support to 2-methyl-5-
propionylfuran [FL-no: 13.155] (DG SANCO, 2012), and therefore, this substance will not be further
considered in this FGE. Because the withdrawal came before publication of the Union List2, this
substance was not included in this list. However, since it was included in the ‘Register’ (Commission
Decision 1999/217/EC), for the sake of completeness, it is still mentioned in this revision 3 of FGE.13.
For 24 candidate substances [FL-no: 13.011, 13.102, 13.108, 13.113, 13.114, 13.122, 13.124,
13.127, 13.129, 13.130, 13.132, 13.133, 13.135, 13.136, 13.139, 13.141, 13.143, 13.144, 13.145,
13.146, 13.149, 13.178, 13.185 and 13.199], the CEF Panel concluded, in FGE.13Rev2, that they
would be of ‘No safety concern at estimated levels of intake as flavouring substances’ based on the
MSDI approach.
For 19 of the 24 substances evaluated through the Procedure [FL-no: 13.011, 13.102, 13.108,
13.113, 13.114, 13.122, 13.127, 13.129, 13.132, 13.133, 13.135, 13.136, 13.139, 13.141, 13.143,
13.146, 13.149, 13.178 and 13.185], mTAMDI values were above the threshold of concern for the
respective Cramer class. For substance [FL-no: 13.130], no use levels were provided.
FGE Adopted Link Substances
FGE.13 27.4.2005 https://www.efsa.europa.eu/en/efsajournal/pub/215 18
FGE.13Rev1 26.11.2009 http://www.efsa.europa.eu/en/efsajournal/pub/1403 25
FGE.13Rev2 6.7.2011 https://www.efsa.europa.eu/en/efsajournal/pub/2313 27
FGE.13Rev3 15.12.2020 https://www.efsa.europa.eu/en/efsajournal/pub/6386 26
The present revision of FGE.13, FGE.13Rev3 concerns the evaluation of two alkylfurans, namely
2-ethyl-5-methylfuran [FL-no: 13.125] and 2-octylfuran [FL-no: 13.162] based on new genotoxicity and
toxicity data submitted on a supporting substance, 2-pentylfuran [FL-no: 13.059], from FGE.67Rev3.
The present revision of FGE.13 (FGE.13Rev3) deals with 26 flavourings substances of which 24
have been already evaluated to be of no safety concern in the previous revisions of FGE.13. A
summary of the history of the evaluation of the substances in FGE.13 is presented in Figure 1.
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1.4. Presentation of the substances in FGE.13Rev3
All candidate substances in FGE.13Rev3 are furan derivatives and can be divided into two main
groups (I and II), depending on the absence/presence of sulfur-containing substituents. Within these
two main groups, a further differentiation in subgroups is introduced, depending on the nature of the
ring substituents and the number and position of the sulfur-containing substituents. The subgrouping
of the candidate substances is shown below. The candidate substances are structurally related to 53
flavouring substances (supporting substances) evaluated by the JECFA at their 55th, 59th, 65th, 69th,
76th and 86th meetings (JECFA, 2001a,b, 2002, 2003, 2006b, 2009a, 2012, 2019) and by EFSA (EFSA,
2004b).
Only group Ic, which includes the substances evaluated in FGE.13Rev3 is described. No descriptions
are given for groups Ia, Ib, IIa, IIb, IIc and IId which can be found in FGE.13Rev2 (EFSA CEF Panel,
2011).
Main group I. Non-sulfur-containing Furan Derivatives
Subgroup Ic: Alkyl-substituted furans
The two candidate substances in subgroup Ic are alkyl substituted furans [FL-no: 13.125 and
13.162] without any further functional groups. These two candidate substances are closely related to
four supporting substances [FL-no: 13.059, 13.069, 13.106, 13.148] evaluated at the 69th, 76th and
86th JECFA meeting (JECFA, 2009a, 2012, 2019) in a group of ‘Furan-substituted substances’. These
four supporting substances have been considered by EFSA in FGE.67Rev3 (EFSA FAF Panel, 2021).
Previously, for this subgroup also [FL-no: 13.029, 13.030, 13.092 and 13.103] were identified as
supporting substances for the two candidates in subgroup Ic in FGE.13Rev2. However, these
substances are no longer supported by industry (see FGE.67Rev3). Therefore, they have been deleted
from subgroup IV of FGE.67Rev3. The substances [FL-no: 13.029, 13.030, 13.092] were already
deleted from the Union List.7
The candidate substances considered in FGE.13Rev3 and the supporting substances for each
subgroup are reported in Table 1. In the last column of Table 1, the status of the evaluation by EFSA
of the supporting substances and of individual members of FGE.13 is presented, based on the
evaluation in FGE.13Rev2, i.e. before consideration of the information received by EFSA that leads to
the present revision 3 of this FGE. In the meantime some substances have been withdrawn by industry
for use as flavourings substances. This is also taken into account in the table.
FGE.13, 2005
•18 substances split into 2 
subgroups:
• Subgroup I: 9 furfuryl alcohol 
derivatives 
•Subgroup II: 9 sulphur-containing 
furan derivatives
•17 substances evaluated through 
the Procedure “no safety concern 
based on MSDI”;
• 1 substance                              
5-hydroxymethylfurfuraldehyde 
[FL-no: 13.139] not evaluated 




•25 substances considered in 
FGE.13Rev1 in 2 main groups and 
additional subgroups:
•11 substances in Group I 
(subgroups Ia and Ib);
• 14 substances in Group II 
(subgroups IIa to IIe)
• 3 substances [FL-no: 13.125, 
13.139, 13.162] not evaluated 
through Procedure due to 
genotoxicity concern;
•For 2 substances [FL-no: 13.185, 
13.199] missing data on 
stereoisomerism;




•27 substances considered in 
FGE.13Rev2:
•[FL-no: 13.155] allocated to 
subgroup Ib
•[FL-no: 13.125 and 13.162] 
allocated to subgroup Ic
•3 substances [FL-no: 13.125, 
13.155 and 13.162] not 
evaluated through Procedure 
due to genotoxicity concern;
•24 substances “no safety 




•1 substance [FL-no: 13.155] not 
supported and not included in the 
Union List
•26 substances considered in 
FGE.13Rev3:
•24 substances already evaluated 
through the Procedure in previous 
revisions;
•2 substances [FL-no: 13.125 and 
13.162] to be evaluated.
Added 7 substances:
[FL-no: 13.125, 13.135, 




Figure 1: Summary of the history of evaluation of the substances in FGE.13
7 Commission Regulation (EU) No 246/2014 of 13 March 2014 amending Annex I to Regulation (EC) No 1334/2008 of the
European Parliament and of the Council as regards removal from the Union list of certain flavouring substances. OJ L74,
14.3.2014, p. 58–60.
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For the sake of completeness, the information on identity of all substances is maintained in various
tables of this FGE. Information on specifications is only maintained for the substances which are
currently in the Union List (see Appendix B). For substances that are no longer in the Union List,
FGE.13Rev2 can be consulted.
A summary of the safety evaluation of the flavouring substances in FGE.13 and further revisions is
presented in Appendix D, Table D.1.
The names and structures of the supporting substances for the candidate substances [FL-no:
13.125 and 13.162] considered in FGE.13Rev3 (from FGE.67Rev3) are listed in Appendix E, Table E.1,
together with their evaluation status (JECFA, 2019).
Table 1: FGE.13Rev3 – candidate and supporting substances divided into subgroups of related
chemical structures. Substances listed in bold are the candidate substances in this FGE.
The supporting substances from the 55th, 59th, 65th, 69th, 76th and 86th JECFA
meetings and EFSA (EFSA, 2004b) are in normal type face
FL-no
JECFA-no
EU Register name Structural formula
EFSA status according to
FGE.13Rev2
Main Group I: non-sulfur-containing furan derivatives




O FGE.13 Rev1 – no safety concern
13.102 Butyl 2-furoate O
O
O
FGE.13 – no safety concern
13.122 Ethyl 2-furoate O
O
O





FGE.13 Rev1 – no safety concern
13.129 Furfuryl but-2-enoate O
O
O




O FGE.13 Rev2 – no safety concern
13.132 Furfuryl hexanoate O
O
O





FGE.13 – no safety concern
13.136 2-Furoic acid O
OH
O
















O FGE.66 Rev1 – no safety concern
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FL-no
JECFA-no
EU Register name Structural formula



































FGE.66 Rev1 – no safety concern




Supporting substance from the
Register and evaluated by the AFC
Panel (EFSA, 2004b). Substance





































FGE.66 Rev1 – no safety concern
Subgroup Ib Alkoyl-substituted furans
13.155 2-Methyl-5-propionylfuran
O
O Not supported as candidate
substance in this FGE (DG SANCO,






O To be evaluated in FGE.67Rev3
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FL-no
JECFA-no
EU Register name Structural formula































O To be evaluated in FGE.67Rev3
Subgroup Ic Alkyl-substituted furans












































To be evaluated in FGE.67Rev3
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FL-no
JECFA-no
EU Register name Structural formula
EFSA status according to
FGE.13Rev2






FGE.13 – no safety concern
13.124 Ethyl furfuryl sulfide
S



















FGE.13 Rev1 – no safety concern
13.145 Methyl 5-methylfurfuryl
sulfide S




































































O FGE.65 Rev1 – no safety concern
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FL-no
JECFA-no
EU Register name Structural formula













































































































FGE.65 Rev1 – no safety concern
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2. Data and methodologies
2.1. Data
The applicant did not provide new toxicity data on 2-ethyl-5-methylfuran [FL-no: 13.125] and on 2-
octylfuran [FL-no: 13.162]. Genotoxicity and toxicity data have been provided for the supporting
substance 2-pentylfuran [FL-no: 13.059] and for 2-acetylfuran [FL-no: 13.054], evaluated in
FGE.67Rev3.
Additional information was provided by the applicant during the assessment process in response to
requests from EFSA sent on 1/4/2015, 18/12/2017, 29/11/2018, 29/4/2020, 15/7/2020 (see
Documentation provided to EFSA n. 6, 26, 27, 30, 31, 32, 3, 4, 21, 23). Moreover, industry provided
updated poundage and use levels data (Documentation provided to EFSA n.22).
The new available data considered in the present revision of FGE.13 are summarised in Table 2.
FL-no
JECFA-no
EU Register name Structural formula
















FGE.65 Rev1 – no safety concern
Subgroup IId Polysulfides








tetrasulfide(b) S SS S
O
O
FGE.65 Rev1 – no safety concern
(a): Commission Regulation (EU) No 246/2014 of 13 March 2014 amending Annex I to Regulation (EC) No 1334/2008 of the
European Parliament and of the Council as regards removal from the Union list of certain flavouring substances. OJ L74,
14.3.2014, p. 58–60.
(b): Supporting substances for each subgroup.
(c): Letter from DG-SANTE to EFSA (DG SANTE, 2020a).
(d): Letter from DG-SANTE to EFSA (DG SANTE, 2020b).














Appendix C (Tables C.2
and C.6); Section 3.2
EFFA (2017, 2020c)
13.162 2-Octylfuran Use levels, poundage
data
Appendix C (Tables C.2
and C.6); Section 3.2
EFFA (2017, 2020c)




Appendix H (Tables H.1,
H.2), Appendix I
(Table I.1);
Sections 3.3.2 and 3.3.3
New York Medical College
(2012), Covance (2014),
Charles River (2020b), Gulf
South Research Institute
(1971a,b), Product Safety
Labs (2016, 2017), EFFA
(2020a,b)




Appendix H (Tables H.1,
H.2), Appendix I
(Table I.1);





(a): Data on the supporting substance 2-pentylfuran and 2-acetylfuran are evaluated in FGE.67Rev3.
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In addition, the following references were used:
– JECFA monograph and report of the 65th meeting (JECFA, 2006a,b), JECFA monograph and
report of the 69th meeting (JECFA, 2009a,b), 76th JECFA report (JECFA, 2012) and 86th
JECFA report (JECFA, 2019).
– EFSA scientific opinion on FGE.67Rev2 (EFSA CEF Panel, 2015a).
– EFSA scientific opinion on FGE.67Rev3 (EFSA FAF Panel, 2021).
– EFSA scientific opinion on FGE.13Rev2 (EFSA CEF Panel, 2011).
2.2. Methodologies
This opinion was elaborated following the principles described in the EFSA Guidance on
transparency with regard to scientific aspects of risk assessment (EFSA Scientific Committee, 2009)
and following the relevant existing guidance documents from the EFSA Scientific Committee. The
assessment strategy applied for the evaluation programme of flavouring substances, as laid down in
Commission Regulation (EC) No 1565/2000, is based on the Opinion on a Programme for the
Evaluation of Flavouring substances of the Scientific Committee on Food (SCF, 1999).
2.2.1. Procedure for the safety evaluation of flavouring substances
The approach for safety evaluation of chemically defined flavouring substances as referred to in
Commission Regulation (EC) No 1565/2000, named the ‘Procedure’, is described in Appendix A.
2.2.2. Approach used for the calculation of exposure
The approach used for calculation of the intake of the flavouring substances is described in
Appendix A (point ‘a) Intake’) and in Appendix C (Section C.2 ‘mTAMDI calculation’).
3. Assessment
The 24 flavouring substances already evaluated in the previous revisions of FGE.13 and substance
[FL-no: 13.155], which is no longer supported as a candidate substance, will not be further discussed.
Thus, in FGE.13Rev3, only two substances [FL-no: 13.125 and 13.162] will be evaluated. Nevertheless,
for the sake of completeness, the information for all 27 substances is maintained in the various tables
of this FGE.
3.1. Specifications
Purity criteria for the 26 candidate substances (NB: [FL-no: 13.155] is no longer a candidate
substance) have been provided by the flavouring industry (JECFA, 2001c; EFFA, 2003, 2004b; Flavour
Industry, 2009).
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/20003, the
information is adequate for all 26 candidate substances. However, the Panel noted that:
• the chemical name of [FL-no: 13.178] should be changed from 3-[(2-furfuryl)dithio]-2-methyl-
furan to 3-[(2-furanylmethyl)dithio]-2-methylfuran;
• the chemical name of [FL-no: 13.185] should be changed from 3-[(2-furfuryl)dithio]-2-
butanone to 3-[(2-furanylmethyl)dithio]-2-butanone;
• the CAS no. of [FL-no: 13.011] should be changed from 623-20-1 to 53282-12-5 and the CAS
no. of [FL-no: 13.129] should be changed from 59020-84-7 to 136678-63-2.
No new information on specifications has been provided for the substances in FGE.13Rev3 since
the previous revision of the FGE. The available specifications including minimum assay values are
presented in table format in Appendix B.
Stereoisomers
It is recognised that geometrical and optical isomers of substances may have different properties.
Their flavour may be different; they may have different chemical properties resulting in possible
variation of their absorption, distribution, metabolism, elimination and toxicity. Thus, information must
be provided on the configuration of the flavouring substance, i.e. whether it is one of the geometrical/
optical isomers, or a defined mixture of stereoisomers. The available specifications of purity will be
considered in order to determine whether the safety evaluation carried out for candidate substances
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for which stereoisomers may exist can be applied to the material of commerce. Flavouring substances
with different configurations should have individual chemical names and codes (CAS number, FLAVIS
number etc.).
Three of the 26 candidate substances possess a chiral centre [FL-no: 13.127, 13.185 and 13.199].
For all three substances, the industry has informed that the commercial substance is the racemate
(EFFA, 2010).
Two of the 26 candidate substances can exist as geometrical isomers [FL-no: 13.011 and 13.129],
and in both cases, industry has informed that the commercial substance is the (E)-isomer (see
Appendix B).
3.2. Intake data
3.2.1. Natural occurrence in food
For the two candidate substances that are evaluated in FGE.13Rev3, a search in VCF online database
(VCF (2020) showed for [FL-no: 13.125] natural occurrence in e.g. barley, beef, coffee, hazelnut, fish,
shrimps and soybean. Quantitative data were available for hazelnut (0.115–2.412 mg/kg) and for
shrimps (0.011 mg/kg). For [FL-no: 13.162] natural occurrence was identified qualitatively in beef,
coriander seed, hazelnut, olive, potato, walnut and whey protein. In chicken, trace amounts were
reported. For the remaining substances in this group of flavouring substances, information on natural
occurrence in food has been presented in FGE.13Rev2.
3.2.2. Estimated daily per capita intake (MSDI approach)
The intake estimation is based on the maximised survey-derived daily intake (MSDI (SCF, 1999))
approach. The data underlying this approach are obtained from surveys on annual production volumes
in Europe. These surveys were initially conducted in 1995 by the International Organization of the
Flavour Industry (IOFI), in which flavour manufacturers reported the total amount of each flavouring
substance incorporated into food sold in the EU during the previous year (IOFI, 1995). The intake
approach does not consider the possible natural occurrence in food.
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is
consumed by 10% of the EU population8 (Eurostat, 1998). This is derived for candidate substances
from estimates of annual volume of production provided by Industry and incorporates a correction
factor of 0.6 to allow for incomplete reporting (60%) in the industry surveys (SCF, 1999).
The total annual volume of production of the 26 candidate substances for use as flavouring
substances in Europe has been reported to be approximately 360 kg (EFFA, 2003, 2004a, 2020c;
Flavour Industry, 2009, 2010) and for 42 supporting substances approximately 7800 kg (IOFI, 1995;
EFFA, 2004a, 2009, 2011, 2020b).
On the basis of the annual volumes of production reported for the 26 candidate substances, the
daily per capita intakes for each of these flavourings have been estimated (Appendix C, Table C.6).
More than 85% of the total annual volume of production for the candidate substances is accounted by
one candidate substance, 4,5-dihydro-3-mercapto-2-methylfuran [FL-no: 13.108]. The estimated daily
per capita intake of this candidate substance from use as a flavouring substance is 37 lg, and below
1.2 lg for each of the remaining candidate substances (Table C.6).
New information on production figures has been provided. Poundage data for [FL-no: 13.125 and
13.162] are 0.5 kg and 1 kg, respectively (EFFA, 2020c).
3.2.3. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI)
The method for calculation of modified theoretical added maximum daily intake (mTAMDI) values is
based on the approach used by SCF up to 1995 (SCF, 1995).
The assumption is that a person may consume a certain amount of flavourable foods and
beverages per day.
Updated use levels for the two candidate substances [FL-no: 13.125 and 13.162] have been
provided (EFFA, 2017). No use levels are available for [FL-no: 13.130].
8 EU figure 375 millions (Eurostat, 1998). This figure relates to EU population at the time for which production data are
available, and is consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No production data
are available for the enlarged EU.
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The detailed information on use levels and the comparison of the MSDI and mTAMDI intake
estimations are reported in Appendix C (Tables C.2, C.6) for 25 candidate flavouring substances in
FGE.13Rev3. In the case where different use levels were reported for different food categories the
highest reported normal use level was used for the calculation of mTAMDI.
According to the Flavour Industry, the normal use levels for these 25 candidate substances are in
the range of 0.001–20 mg/kg food, and the maximum use levels are in the range of 0.003–100 mg/kg
food (EFFA, 2003, 2004b, 2017; Flavour Industry, 2009).
The mTAMDI values for the four candidate substances from structural class II (see Appendix C)
range from 160 to 3,900 lg/person per day. For 21 candidate substances from structural class III the
mTAMDIs range from 49 to 3,900 lg/person per day.
For detailed information on use levels and intake estimations based on the mTAMDI approach, see
Appendix C.
3.2.4. Considerations of combined intakes from use as flavouring substances
Because of structural similarities of candidate and supporting substances, it can be anticipated that
many of the flavourings are metabolised through the same metabolic pathways and that the
metabolites may affect the same target organs (see Section 3.3.1). Further, in case of combined
exposure to structurally related flavourings, the pathways could be overloaded. Therefore, combined
intake should be considered. As flavouring substances not included in this Flavouring Group Evaluation
may also be metabolised through the same pathways, the combined intake estimates presented here
are only preliminary. Currently, the combined intake estimates are only based on MSDI exposure
estimates, although it is recognised that this may lead to underestimation of exposure. After
completion of all FGEs, this issue should be readdressed. The combined exposure is calculated for each
subgroup considering also the supporting substances. In the case of subgroup Ic, the combined
exposure will take into account exposures to [FL-no: 13.125 and 13.162], and to the supporting
substances from FGE.67Rev3 [FL-no: 13.059, 13.069, 13.106, 13.148].
The total estimated combined daily per capita intake of structurally related flavourings is estimated
by summing the MSDI for individual candidate substances evaluated through the Procedure. The 26
candidate substances are structurally related to 42 supporting substances evaluated by the JECFA at
their 55th, 59th, 69th and 86th meetings (JECFA, 2001a,b, 2002, 2003, 2009b, 2019) or by EFSA
(EFSA, 2004b). This number of 42 does not include flavouring substances which are no longer
supported by industry or have been deleted from the Union List (see Table 1).
For the present evaluation, the combined intake will be estimated for each subgroup as defined in
Section 1.4. The combined intake is estimated for candidate substances together with their supporting
substances. In cases where the subgroups include substances belonging to different structural classes
according the Cramer classification, the combined intake will be estimated for each structural class,
separately. For example, in the case of subgroup Ic, the combined exposure will take into account
exposures to candidate substances [FL-no: 13.125 and 13.162] and to the supporting substances from
FGE.67Rev3 [FL-no: 13.059, 13.069, 13.106, 13.148], all from structural class III. Each combined
intake estimate will be compared to the threshold of concern value for the relevant structural class. In
the table below, the combined intake is given for each subgroup and structural class within the
subgroups for both candidate and supporting substances.
Table 3: Total combined intake estimates (based on MSDI) for the different subgroups in
FGE.13Rev3. The combined intake for candidate and supporting substances in each
structural class is also presented
Combined intake based on the MSDI approach (lg/capita per day)







SC II SC III SC III SC II SC III SC III SC III SC III
Candidate
substances
1.0 2.6 0.18 0.0024 2.0 37 0.25 0.0024
No of substances 4 6 2 1 6 2 4 1
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On the basis of the reported annual production volumes in Europe (EFFA, 2003, 2004b, 2017,
2020b,c), the combined estimated daily per capita intake as flavourings is below the threshold of
concern for the structural class for all subgroups and structural classes except for subgroup Ia
(structural class II) and subgroup IIb (structural class III), where the total combined intakes for
candidate and supporting substances are 850 and 92 lg/capita per day, respectively. These estimates
exceed the threshold for structural class II substances of 540 lg/capita per day, and for structural
class III substances of 90 lg/capita per day. However, for subgroup Ia, more than 50% of the total
combined daily per capita intake of 850 lg comes from furfural for which, together with the furfural
component of furfural diethyl acetal, an ADI of 0.5 mg/kg bw per day has been established by EFSA
(EFSA, 2004b). For subgroup IIb, the total combined intake for the class III substances of 92 lg/
capita per day also exceeds the threshold for the structural class of 90 lg/person per day. One of the
substances in the group of supporting substances from structural class III, 2-methyltetrahydrofuran-3-
thiol [FL-no: 13.160], also accounts for more than 50% of the combined MSDI for this group. In a 90-
day toxicity study by Kappeler (2014), a NOAEL of 5 mg/kg bw per day for male and female Crl:CD
(SD) rats, could be established for 2-methyltetrahydrofuran-3-thiol in FGE.65Rev1 (EFSA CEF Panel,
2015b). The MSDI of 92 lg/capita per day correspond to 0.0015 mg/kg bw per day, which provides a
margin of safety of more than 3,000 for this subgroup.
The combined estimated daily per capita intake of the substances in subgroup Ic [FL-no: 13.125
and 13.162] plus those for the four supporting substances (from FGE.67Rev3) assigned to structural
class III is 4.1 lg, which does not exceed the threshold of concern of 90 lg/person per day for
substances belonging to structural class III.
The background figures for the different exposure estimates are given in Appendix C.
3.3. Biological and toxicological data
3.3.1. Absorption, Distribution, Metabolism and Elimination (ADME)
The candidate substances in FGE.13Rev3 are furan derivatives which can be divided into subgroups
based on their chemical structure (see Table 4). In FGE.13Rev3 only information on subgroup Ic is
reported. Information on all other subgroups can be retrieved in FGE.13Rev2 (EFSA CEF Panel, 2011).
Combined intake based on the MSDI approach (lg/capita per day)







SC II SC III SC III SC II SC III SC III SC III SC III
Supporting
substances
850 2.6 3.9 2.2 6.9 55 0.89 0.97
No of
substances(a)
10 5 4 2 8 3 4 1
Total 850 5.2 4.1 2.2 8.9 92 1.1 0.97
(a): The total number of supporting substances included in the combined exposure estimates adds up to 37 rather than 42. This
is because in subgroup IIb and subgroup IIc there are no structural class II candidate substances whereas there are two
and three, respectively, among the supporting substances. Therefore, these five supporting substances have not been
included in the combined intake calculations.
Table 4: Candidate substances divided into subgroups of related chemical structures
FL-no EU Register name Structural formula Structural class
Main Group I: non-sulfur-containing furan derivatives
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FL-no EU Register name Structural formula Structural class





































Subgroup Ic Alkyl-substituted furans


























13.145 Methyl 5-methylfurfuryl sulfide
S
O II
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3.3.1.1. Main Group I
Subgroup Ic
The candidate substances in subgroup Ic [FL-no: 13.125 and 13.162] are substituted furans which
in contrast to the candidate substances in subgroup Ia do not bear any functional (carbonyl) groups in
the side chain. Based on the limited data available, also for these substances absorption from the GI-
tract may be anticipated, similar to the subgroup Ia substances. Mono-alkyl furans, such as the
candidate substance 2-octylfuran [FL-no: 13.162], may be subject to oxidation (possibly epoxidation of
the unsubstituted double bond in the furan ring) followed by ring opening and rearrangement to keto-
aldehydes. For several 2-alkyl-substituted furans reactivity of their metabolites towards proteins and
DNA has been demonstrated, resulting in toxicity to liver and kidneys. Oxidation of the C1′-carbon of
the alkyl substituent may result in the formation of an a,b-unsaturated ketone with the carbonyl group
connected to the aromatic double bonds in the furan ring, similar to acetophenone. A study on the
metabolism of 2,5-dimethylfuran demonstrated that this substance is subject to ring-opening resulting
in the formation of a reactive intermediate, probably hex-3-ene-2,5-dione, which showed reactivity
towards free protein-thiol and amino groups.
Concerning the potential neurotoxicity of the unsaturated gamma diketone hex-3-ene-2,5-dione,
the Panel concluded in FGE.67Rev3 (EFSA FAF Panel, 2021) that there is no solid ground to raise a
concern for potential formation of neurotoxic protein adducts.
The ring-opening products of alkylfurans are reactive towards DNA and proteins and the two
candidate substances in subgroup Ic are examples of these alkylfurans. Therefore, it is concluded that
the candidate substances included in main group I cannot be predicted to be metabolised only to
innocuous compounds.
A detailed description of the toxicokinetic features of alkylfurans, among which [FL-no: 13.125 and
13.162] is reported in Appendix F.




































(a): Substance not supported (DG SANCO, 2012) and not included in the Union List.
(b): Determined with OECD Toolbox (version 4.3.1 available online https://www.oecd.org/chemicalsafety/risk-assessment/oecd-
qsar-toolbox.htm).
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3.3.2. Genotoxicity studies
Genotoxicity studies were available only on some of the candidate substances included in main
group I or on their related supporting substances. In FGE.13Rev3, only data related to the substances
in subgroup Ic are reported. Information on other substances are available in FGE.13Rev2 (EFSA CEF
Panel, 2011).
No data are available on the genotoxic properties of the two candidate substances [FL-no: 13.125
and 13.162] in subgroup Ic.
Several studies were found with 2-methylfuran [FL-no: 13.030]9 and 2,5-dimethylfuran [FL-no:
13.029].9 Negative results were obtained in a limited bacterial reverse gene mutation test with
S. Typhimurium (TA97 and TA100 strains only, no data on cytotoxicity, no duplicate trial (Shinohara
et al., 1986)). However, a concentration-related positive response with limited validity (e.g. no clear
data on cytotoxicity; no clear description of scoring criteria) was obtained with both substances in a
chromosome aberration test in Chinese hamster ovary cells with and without metabolic activation in
the presence or absence of metabolic activation (Stich et al., 1981). Both substances also gave a
positive response in a rec-assay for bacterial DNA-repair (Shinohara et al., 1986), but the predictive
value of this test system is considered to be limited.
For 2-alkyl- and 2,5-dialkyl-substituted furans, formation of reactive ring opening products cannot
be excluded (see Section 3.3.1 and Appendix F). These reactive intermediates can bind covalently to
DNA, which might result in genotoxic events. In an alternative metabolic pathway, these flavouring
substances may also be converted to ketones which are structurally related to the substances in
former subgroup Ib, and for these substances, a concern for genotoxicity has been identified (based
on previously reported data on the supporting substance 2-acetylfuran [FL-no: 13.054] from FGE.67).
Therefore, owing to the anticipated metabolism of the two candidate substances in subgroup Ic into
possible genotoxic metabolites a concern for genotoxicity was raised. However, newly submitted
genotoxicity data are available for the supporting substances 2-acetylfuran [FL-no: 13.054] and 2-
pentylfuran [FL-no: 13.059] evaluated in FGE.67Rev3 (EFSA FAF Panel, 2021). The summary of that
evaluation is reported below, for detailed description of the evaluation of the genotoxicity studies on
[FL-no: 13.054, 13.059], see FGE.67Rev3 (EFSA FAF Panel, 2021).
3.3.2.1. Genotoxicity evaluation of the supporting substance 2-pentylfuran [FL-no:
13.059] from FGE.67Rev3
For 2-pentylfuran [FL-no: 13.059], no in vitro data were available to the Panel. Industry submitted
an in vivo comet assay in mice (New York Medical College, 2012). The Panel considered that this study
was not sufficiently reliable to conclude on the genotoxicity of 2-pentylfuran in mice.
2-Pentylfuran was tested in vivo in a combined comet assay and micronucleus assay in rats. Results
from the comet assay in liver were negative, suggesting that 2-pentylfuran did not induce gene
mutations or clastogenic effects in the tissue in which the potential for activation to genotoxic
metabolites is expected. In the same study, 2-pentylfuran did not increase micronucleated cell
frequency in bone marrow. However, the Panel noted that no decrease in the percentage of
polychromatic erythrocytes was observed, and hence, exposure of the bone marrow to 2-pentylfuran
could not be confirmed. No information was available from blood analyses to show systemic exposure.
Moreover, the clinical signs of toxicity observed in this study or in an additional 90-day repeated dose
toxicity study in rats are not sufficient to demonstrate the systemic exposure to the tested substance.
Based on the observations above, the Panel considered that the available in vivo micronucleus
assay is not adequate to rule out potential chromosomal damage induced by 2-pentylfuran [FL-no:
13.059].
To resolve the above concerns, the Panel requested to test 2-pentylfuran [FL-no: 13.059] in an
in vitro micronucleus assay in human peripheral blood lymphocytes with fluorescence in situ
hybridisation (FISH) analysis. In this in vitro test, 2-pentylfuran did not induce micronuclei (MN),
indicating that the testing substance does not induce chromosomal damage. Based on the available
data, the Panel concluded in FGE.67Rev3 that for 2-pentylfuran [FL-no: 13.059], the concern for
genotoxicity is ruled out.
9 This substance has been deleted from the Union list, see Commission Implementing Regulation (EU) No 246/2014 of 13 March
2014 amending Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council as regards removal
from the Union list of certain flavouring substances. OJ L 74, 14.3.2014, p. 58–60.
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3.3.2.2. Genotoxicity evaluation of the supporting substance 2-acetylfuran [FL-no:
13.054] from FGE.67Rev3
From studies considered in previous versions of this FGE, a concern for genotoxicity was raised for
2-acetylfuran (see above). The studies showed limitations and the CEF Panel decided that additional
information was necessary for its evaluation. Following the request of the Panel, an in vivo combined
gene mutation and micronucleus assay in transgenic mice was submitted. 2-Acetylfuran did not
increase the mutation frequency in liver and duodenum, indicating that the testing substance does not
induce gene mutations. In the same study, 2-acetylfuran did not increase the percentage of
micronucleated cells in peripheral blood. However, the Panel noted that in the micronucleus arm of the
study, no positive control was included. Moreover, no decrease in the percentage of reticulocytes was
observed, and hence, systemic exposure to 2-acetylfuran could not be confirmed. The clinical signs of
toxicity observed in this study and in a 28/90-day repeated dose toxicity study in rats (Bio-Research
Laboratories, 1985) were not sufficient to demonstrate the systemic exposure to the tested substance
in mice. The use of toxicity data from a different species as evidence of systemic exposure is not
recommended by EFSA Scientific Committee (2017a).
Based on the observations above, the Panel considered that for 2-acetylfuran, there is no concern
for gene mutations. However, the available in vivo micronucleus assay was not adequate to rule out
potential chromosomal damage induced by 2-acetylfuran [FL-no: 13.054]. Therefore, the
Panel requested to test 2-acetylfuran in an in vitro micronucleus assay in human peripheral blood
lymphocytes with FISH analysis. This study showed that 2-acetylfuran did not induce MN, indicating
that the substance does not induce chromosomal damage and is not aneugenic. Based on the
available data, the Panel concluded in FGE.67Rev3 that for 2-acetylfuran [FL-no: 13.054], the concern
for genotoxicity is ruled out.
The Panel considered that the genotoxicity data on the supporting substances 2-acetylfuran [FL-no:
13.054] and 2-pentylfuran [FL-no: 13.059] allow to rule out the genotoxicity concern for these two
supporting substances. Therefore, the structurally related candidate substances [FL-no: 13.125 and
13.162] can be evaluated through the procedure.
3.3.3. Toxicological data
No toxicity data have been provided for [FL-no: 13.125 and 13.162]. However, toxicity studies are
available for the supporting substance 2-pentylfuran [FL-no: 13.059] and for 2-acetylfuran [FL-no:
13.054] evaluated in FGE.67Rev3. Summary results of the toxicity studies described below are
reported Appendix I, Table I.1.
3.3.3.1. 2-Pentylfuran [FL-no: 13.059] – toxicity studies
2-Pentylfuran was tested in a single dose oral acute toxicity study in Swiss Webster mice at these
doses: 0, 800, 1,000, 1,260, 1,600, 2,000 mg/kg bw (Gulf South Research Institute, 1971a, only data
summary available). The LD50 derived was 1,185 mg/kg bw for males and 1,220 mg/kg bw for
females.
2-Pentylfuran was tested in a 90-day toxicity study in Sprague Dawley rats (Gulf South Research
Institute, 1971b), administered in the diet at 25.6 mg/kg per day. Average liver weights of males and
liver and kidney weights of female were statistically significant higher than control. The study authors
considered that this result was due to a low average organ weight in control and not to a real
enlargement of tissues in treated animals. Histological lesions were observed in lungs, which were
associated to a virus infection. No other histological findings were observed.
The Panel considered to base the toxicological evaluation on a more recent 90-day toxicity study
(Product Safety Labs, 2017) where three dose levels were tested and which is compliant with OECD
TG 408 and good laboratory practice (GLP) principles.
2-Pentylfuran was tested in a 90-day toxicity study in CRL Sprague-Dawley® CD® IGS rats (10/sex
per dose group). 2-Pentylfuran was formulated in corn oil and administered at dose levels of 0, 30,
100 and 150 mg/kg bw per day (Product Safety Labs, 2017).
All animals survived until the end of the study.
Statistical significant changes were observed in several haematology parameters and clinical
chemistry parameters, which correlated with histopathology findings in spleen and liver.
The main effects of 2-pentylfuran in the rat are haematological effects, in particular on the red
blood cells and, related to this, effects on reticulocyte counts and on spleen. The test substance
appears to increase the turn-over of erythrocytes.
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The main effect in the liver was centrilobular hepatocellular hypertrophy, which was accompanied
by an increase in relative and absolute liver weights. Some indication for liver toxicity was obtained
from the increase in plasma sorbitol dehydrogenase, but other clinical chemistry parameters and
histopathology did not support this.
The results for all haematological, clinical chemistry, urinalysis parameters and the data on body
and liver weight changes were subjected to dose-response modelling, using the EFSA PROAST web
tool,10 in line with the EFSA Scientific Committee guidance document (EFSA Scientific Committee,
2017b). Instead of using the default value of 5% for the BMR, the Panel employed endpoint-specific
benchmark responses (BMR), based on the theory developed by Slob (2017). This theory takes better
account of the natural variability in the measured parameters than the default BMRs. This results in
biologically more plausible BMRs and subsequently more plausible BMDLs.
The BMDL for mean corpuscular volume was the lowest BMDL identified among the haematological
parameters (14 and 25.4 mg/kg bw per day for males and females, respectively), based on a BMR of
2.6%.
Among the clinical chemistry data, the BMDL of plasma total bilirubin (which amounted to 8.51 or
18.3 mg/kg bw per day for males and females, respectively) was chosen based on a BMR of 22%.
For the decrease in body weights and the increases in absolute and relative liver weights BMDLs
could be estimated. The lowest reliable BMDL for these parameters were 52.6 and 29.9 mg/kg bw per
day for increased absolute liver weight in males and females, respectively, based on a BMR of 15%.
The Panel concluded that for the evaluation of 2-pentylfuran and the structurally related flavouring
substances, the BMDL of 8.51 mg/kg bw per day in males can be used as the reference point, as all
other reliable BMDLs were higher than this BMDL for bilirubin. More details and graphical
representation are reported in FGE.67Rev3 (EFSA FAF Panel, 2021).
3.3.3.2. 2-Acetylfuran [FL-no: 13.054] – Repeated-dose toxicity studies
2-Acetylfuran was tested in Sprague-Dawley CD rats in a combined 28-day and 90-day toxicity
study (Bio-Research Laboratories, 1985). The study was conducted in compliance with the United
States Food and Drug Administration’s Good Laboratory Practice Regulations.
Groups of male and female Sprague-Dawley rats were exposed through the diet to 0, 5, 25 or 100
mg 2-acetylfuran/kg bw per day (nominal dosing).
Results after 28 days of exposure
In the animals of the 100 mg/kg group, a statistically significant decrease in body weight was
observed in males and females at week 3 (–15 or –35%, respectively). In these animals also a
decreased feed consumption (–15% in the males and –17% in the females) was observed. At week 4,
the animals were sacrificed together with half of the 5 mg/kg bw and control group animals. In the
100 mg/kg male animals, glucose and alkaline phosphatase in serum were significantly decreased and
blood urea nitrogen (BUN) was significantly increased. For glucose and alkaline phosphatase in the
females, a similar change was observed as in the males, but statistical significance was not reached. In
females, BUN was not affected. A significant increase in relative liver weight was observed in males
and females dosed at 100 mg/kg per day. In males also an increase of relative gonad (testis +
epididymis) weight was observed. Other parameters in haematology, urinalysis, clinical chemistry or
organ weights and histopathology were not affected. No adverse effects were observed in the animals
from the 5 mg/kg group.
Results after 90 days of exposure
At study termination, the body weights of the males and females in the 25 mg/kg bw dose group
were statistically significantly lower (by 10%) than those of the control animals. The decreases in body
weight were rather limited and connected to a reduced feed consumption (–4% in the males and
–15% in the females). Since no findings attributable to treatment were noted in the clinical,
haematological and histopathological examinations or in the clinical chemistry and urinalysis
parameters, the Panel identified an NOAEL of 25 mg/kg bw per day (nominal value) from this study,
which is the highest dose tested up to 90-day of exposure. This NOAEL is equal to 22.6 mg/kg bw per
day in males and 27 mg/kg bw per day in females.
10 https://efsa.openanalytics.eu/ freely available
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3.4. Application of the Procedure for the safety evaluation of flavouring
substances
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach.
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its
corresponding threshold of concern, the Panel requires more precise data on use and use levels. For
comparison of the intake estimations based on the MSDI approach and the mTAMDI approach, see
Section 3.2 and Appendix C.
Based on new experimental data on genotoxicity on the structurally related substances
2-acetylfuran and 2-pentylfuran [FL-no:13.059] (FGE.67Rev3), which rule out the concerns for
genotoxicity for [FL-no: 13.125 and 13.13.162], the Procedure for the safety evaluation of flavouring
substances as outlined in Appendix A has been applied to the two candidate substances. The stepwise
evaluations are summarised in Appendix A.
Step 1
The two candidate substances [FL-no: 13.125 and 13.162] are allocated to structural class III
according to the decision tree approach by Cramer et al. (1978), see Table 4.
Step 2
Taking into account the metabolic pathways described in Section 3.3.1, the two candidate
substances are not predicted to be metabolised only to innocuous products. Therefore, the evaluation
of 2-ethyl-5-methylfuran [FL-no: 13.125] and 2-octylfuran [FL-no: 13.162] proceeds via the B-side of
the evaluation scheme.
Step B3
The two candidate substances [FL-no: 13.125] and [FL-no: 13.162], which have been assigned to
structural class III, have estimated European daily per capita intakes (MSDI) of 0.06 and 0.12 lg,
respectively (Appendix C). These intakes are below the threshold of concern of 90 lg/person per day
for structural class III. Therefore, the safety evaluation proceeds to step B4 for both candidate
substances.
Step B4
Based on the MSDI exposure estimates for the two candidate substances and the BMDL of
8.51 mg/kg bw per day for increased plasma total bilirubin, observed in a 90-day oral toxicity study
with 2-pentylfuran, adequate margins of safety of 8.5 9 106 and 4.3 9 106 can be calculated for [FL-
no: 13.125] and [FL-no: 13.162], respectively. It is concluded that the use of these two substances as
flavourings in food does not raise a safety concern when based on the MSDI approach.
3.5. Comparison of the intake estimations based on the mTAMDI
approach with the structural class thresholds
For three candidate substances [FL-no: 13.122, 13.136 and 13.139] in structural class II,
evaluated through the Procedure previously, the mTAMDI range from 1,400 to 3,900 lg/person per
day, which is above the threshold of concern for this Cramer class. For another previously
evaluated substance [FL-no: 13.145], the mTAMDI is 160 lg/person per day, which is below its
class threshold of 540 lg/person per day (class II). For the structural class II substance [FL-no:
13.130] no use levels were provided and no mTAMDI can be calculated.
The estimated mTAMDI exposure estimates for 18 [FL-no: 13.011, 13.102, 13.108, 13.113, 13.114,
13.125, 13.127, 13.129, 13.132, 13.133, 13.135, 13.141, 13.143, 13.146, 13.149, 13.162, 13.178 and
13.185] substances assigned to structural class III, range from 160 to 3,900 lg/person per day and
are above the threshold of concern for their structural class (90 lg/person per day). For the remaining
three substances from structural class III [FL no: 13.124, 13.144 and 13.199], the mTAMDIs range
from 49 to 78 lg/person per day, which is below the threshold of concern.
Thus, for four structural class II substances and for 18 structural class III substances, further
information is required. This would include more reliable intake data and then, if required, additional
toxicological data. For comparison of the MSDI and mTAMDI values, see Appendix C.
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4. Discussion
The present revision of FGE.13, FGE.13Rev3, concerns the evaluation, in total, of 26 candidate
flavouring substances. New data included are additional toxicity and genotoxicity studies for the
supporting substances 2-acetylfuran [FL-no: 13.054] and 2-pentylfuran [FL-no: 13.059].
Three of the 26 flavouring substances possess a chiral centre [FL-no: 13.127, 13.185 and 13.199]
industry has informed that the commercial substances are racemates in all three cases. Two of the 26
substances can exist as geometrical isomers [FL-no: 13.011 and 13.129] and in both cases industry
has informed that the commercial substances are the (E)-isomers.
Five candidate substances are classified into structural class II [FL-no: 13.122, 13.130, 13.136,
13.139 and 13.145] and 21 candidate substances are classified into structural class III [FL-no: 13.011,
13.102, 13.108, 13.113, 13.114, 13.124, 13.125, 13.127, 13.129, 13.132, 13.133, 13.135, 13.141,
13.143, 13.144, 13.146, 13.149, 13.162, 13.178, 13.185 and 13.199].
According to the default MSDI approach, the 26 flavouring substances in this group have intakes in
Europe from 0.0012 to 37 lg/capita per day, which are below the thresholds of concern for both
structural class II (540 lg/person per day) and structural class III (90 lg/person per day) substances.
On the basis of the reported annual production volumes in Europe (MSDI approach), the combined
estimated daily per capita intake as flavourings is below the threshold of concern for the structural
class for all subgroups and structural classes except for subgroup Ia, structural class II and subgroup
IIb where the total combined intake for candidate and supporting substances is 850 and 92 lg/capita
per day, respectively, which exceeds the threshold for structural class II substances of 540 lg/person
per day and for structural class III substances of 90 lg/person per day. However, for subgroup Ia,
50% of the combined daily per capita intake of 850 lg results from furfural for which, together with
the furfural component of furfural diethyl acetal, an ADI of 0.5 mg/kg bw per day has been established
by EFSA (EFSA, 2004b). For subgroup IIb, the total combined intake for the class III substances of
92 lg/capita per day also exceeds the threshold for the structural class of 90 lg/person per day. One
of the substances in the group of supporting substances from structural class III,
2-methyltetrahydrofuran-3-thiol [FL-no: 13.160], also accounts for more than 50% of the combined
MSDI for this group. In a 90-day toxicity study by Kappeler (2014), a NOAEL of 5 mg/kg bw per day
for male and female Crl:CD (SD) rats could be established for 2-methyltetrahydrofuran-3-thiol
in FGE.65Rev1 (EFSA CEF Panel, 2015b). The MSDI of 92 lg/capita per day corresponds to
0.0015 mg/kg bw per day, which can provide a margin of safety of more than 3,000.
In previous versions of this FGE, no concerns for genotoxicity were raised for the candidate
substances in subgroups Ia and IIa-d.
However, for the candidate substance in group Ib, in vitro and in vivo genotoxicity data were
available for one supporting substance (2-acetylfuran [FL-no: 13.054]). For subgroup Ic, data on
in vitro genotoxicity were provided for two supporting substances [FL-no: 13.029, 13.030]9
(Appendix G). For one of these, also data on in vivo genotoxicity were provided. In addition, data for a
supporting substance [FL-no: 13.054] for subgroup Ib contribute to the evaluation of the genotoxic
potential of substances in subgroup Ic due to structural similarity of metabolites of the Ic candidates
with the substances in subgroup Ib.
For the supporting substance in subgroup Ib (2-acetylfuran) and for a supporting substance in
subgroup Ic (2-pentylfuran), data were submitted that ruled out the concern for genotoxicity for the
remaining substances in subgroup Ic ([FL-no: 13.125 and 13.162]). The remaining substance in
subgroup Ib [FL-no:13.155] is no longer supported (DG SANCO, 2012).
Based on information on absorption, distribution, metabolism and excretion on candidate and
supporting substances, it cannot be concluded that any of the 26 candidate substances in this FGE is
metabolised only to innocuous metabolites. In FGE13Rev2, the CEF Panel concluded at step B4 of the
Procedure that 24 candidate substances [FL-no: 13.011, 13.102, 13.108, 13.113, 13.114, 13.122,
13.124, 13.127, 13.129, 13.130, 13.132, 13.133, 13.135, 13.136, 13.139, 13.141, 13.143, 13.144,
13.145, 13.146, 13.149, 13.178, 13.185 and 13.199] do not pose a safety concern when used as
flavouring substances at the estimated levels of intake based on the MSDI approach.
In this revision of FGE.13 (Revision 3), the FAF Panel calculated margins of safety of 8.5 9 106 and
4.3 9 106 for the two substances in subgroup Ic [FL-no: 13.125 and 13.162], respectively, at step B4
of the Procedure, by comparison of their MSDI intakes estimates with the BMDL of 8.51 mg/kg bw per
day for the supporting substance 2-pentylfuran. This BMDL was calculated from the data on increased
plasma total bilirubin obtained from a 90-day oral toxicity study with this substance based on a BMR of
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22% change. From these margins of safety, the FAF Panel concluded that the candidate flavouring
substances [FL-no: 13.125 and 13.162] do not raise a safety concern when used as flavouring
substances at the estimated levels of intake based on the MSDI approach.
For three candidate substances [FL-no: 13.122, 13.136 and 13.139] in structural class II, the
mTAMDI intake estimates are above the threshold of concern for this Cramer class. For one structural
class II substance [FL-no: 13.145], the mTAMDI is below the class II threshold and for another
substance [FL-no: 13.130], no use levels were provided, so no mTAMDI can be calculated for this
substance.
The mTAMDI intake estimates for 18 flavouring substances [FL-no: 13.011, 13.102, 13.108, 13.113,
13.114, 13.125, 13.127, 13.129, 13.132, 13.133, 13.135, 13.141, 13.143, 13.146, 13.149, 13.162,
13.178 and 13.185], all assigned to structural class III are above the threshold of concern for their
class. For the remaining three substances from structural class III [FL-no: 13.124, 13.144 and 13.199],
the mTAMDIs are below the threshold of concern.
5. Conclusions
For all 26 candidate substances [FL-no: 13.011, 13.102, 13.108, 13.113, 13.114, 13.122, 13.124,
13.125, 13.127, 13.129, 13.130, 13.132, 13.133, 13.135, 13.136, 13.139, 13.141, 13.143, 13.144,
13.145, 13.146, 13.149, 13.162, 13.178, 13.185 and 13.199], the Panel concluded that they would be
of ‘No safety concern at estimated levels of intake as flavouring substances’ when evaluated based on
the MSDI approach.
For four substances [FL-no: 13.124, 13.144, 13.145 and 13.199], there is no concern when the
exposure was estimated based on the mTAMDI approach.
For 21 substances, more detailed information on uses and normal and maximum use levels are
needed to refine the mTAMDI estimates in order to finalise their evaluation. Upon submission of such
data, additional data on toxicity may become necessary.
For one substance [FL-no: 13.130], use levels are needed to calculate the mTAMDI estimate.
Adequate specifications including complete purity criteria and identity for the materials of
commerce have been provided for all 26 flavouring substances evaluated through the Procedure.
6. Recommendation
The FAF Panel recommends the European Commission to consider:
• to request updated and detailed information on uses and use levels for the following 22
flavouring substances:
[FL-no: 13.011, 13.102, 13.108, 13.113, 13.114, 13.122, 13.125, 13.127, 13.129, 13.130,
13.132, 13.133, 13.135, 13.136, 13.139, 13.141, 13.143, 13.146, 13.149, 13.162, 13.178 and
13.185];
• to change the chemical name of [FL-no: 13.178] from 3-[(2-furfuryl)dithio]-2-methyl-furan to
3-[(2-furanylmethyl)dithio]-2-methylfuran in the Union list (Appendix B – Table B.1);
• to change the chemical name of [FL-no: 13.185] from 3-[(2-furfuryl)dithio]-2-butanone to 3-
[(2-furanylmethyl)dithio]-2-butanone in the Union list (Appendix B – Table B.1);
• to change the CAS no. of [FL-no: 13.011] from 623-20-1 to 53282-12-5 and the CAS no. of
[FL-no: 13.129] from 59020-84-7 to 136678-63-2 in the Union list (Appendix B – Table B.1).
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Abbreviations
ADI Acceptable Daily Intake
AFC Food Additives, Flavourings, Processing Aids and Materials in Contact with Food
BMD Benchmark Dose
BMDL Benchmark Dose lower boundary of confidence interval (95% single sided)
BUN Blood Urea Nitrogen
bw Body weight
CAS Chemical Abstract Service
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CHO Chinese hamster ovary (cells)
CoE Council of Europe
DNA Deoxyribonucleic acid
EC European Commission
EFFA European Flavour Association
EFSA The European Food Safety Authority
EU European Union
FAO Food and Agriculture Organization of the United Nations
FEMA Flavor and Extract Manufacturers Association
FGE Flavouring Group Evaluation
FISH Fluorescence In Situ Hybridization
FLAVIS (FL) Flavour Information System (database)
GI Gastrointestinal
GLP Good Laboratory Practice




IOFI International Organization of the Flavour Industry
IR Infrared spectroscopy
JECFA The Joint FAO/WHO Expert Committee on Food Additives
LD50 Lethal Dose, 50%; Median lethal dose
MN Micronuclei
MS Mass spectrometry
MSDI Maximised Survey-derived Daily Intake
mTAMDI Modified Theoretical Added Maximum Daily Intake
No Number
NOAEL No Observed Adverse Effect Level
NOEL No Observed Effect Level
OECD Organisation for Economic Co-operation and Development
SCF Scientific Committee on Food
SMART Somatic Mutation and Recombination Test
TAMDI Theoretical Added Maximum Daily Intake
UDS Unscheduled DNA Synthesis
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Appendix A – Procedure of the safety evaluation
The approach for a safety evaluation of chemically defined flavouring substances as referred to in
Commission Regulation (EC) No 1565/20003, named the ‘Procedure’, is shown in schematic form in
Figure A.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed on 2
December 1999 (SCF, 1999), which is derived from the evaluation Procedure developed by the Joint
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995,
1996, 1997, 1999).11
The Procedure is a stepwise approach that integrates information on intake from current uses,
structure–activity relationships, metabolism and, when needed, toxicity. One of the key elements in the
Procedure is the subdivision of flavourings into three structural classes (I, II, III) for which
toxicological thresholds of concern (TTCs) (human exposure thresholds) have been specified.
Exposures below these TTCs are not considered to present a safety concern.
Class I contains flavourings that have simple chemical structures and efficient modes of
metabolism, which would suggest a low order of oral toxicity. Class II contains flavourings that have
structural features that are less innocuous, but are not suggestive of toxicity. Class III comprises
flavourings that have structural features that permit no strong initial presumption of safety, or may
even suggest significant toxicity (Cramer et al., 1978). The TTCs for these structural classes of 1,800,
540 or 90 lg/person per day, respectively, are derived from a large database containing data on
subchronic and chronic animal studies (JECFA, 1996).
In step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The
further steps address the following questions:
• Can the flavourings be predicted to be metabolised to innocuous products12 (step 2)?
• Do their exposures exceed the TTC for the structural class (steps A3 and B3)?
• Are the flavourings or their metabolites endogenous13 (step A4)?
• Does a NOAEL exist on the flavourings or on structurally related substances (steps A5 and B4)?
In addition to the data provided for the flavouring substances to be evaluated (candidate
substances), toxicological background information available for compounds structurally related to the
candidate substances is considered (supporting substances), in order to assure that these data are
consistent with the results obtained after application of the Procedure.
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity.
Therefore, the right is reserved to use alternative approaches if data on specific flavourings warranted
such actions.
11 The FAF Panel is aware that a Revised Procedure for the Safety Evaluation of Flavouring agents has been agreed by JECFA
(JECFA, 2016). The EFSA Scientific Committee has developed a modified procedure for evaluation of substances based on the
TTC approach (EFSA Scientific Committee, 2019). However, these developments have no impact on the present evaluation,
which should follow the requirements as set out in Commission Regulation (EC) No 1565/2000.
12 ‘Innocuous products’: products that are known or readily predicted to be harmless to humans at the estimated intakes of the
flavouring agent (JECFA, 1997).
13 ‘Endogenous substances’: intermediary metabolites normally present in human tissues and fluids, whether free or conjugated;
hormones and other substances with biochemical or physiological regulatory functions are not included (JECFA, 1997).
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The following issues are of special importance:
a) Intake
Annual production volumes of the flavouring substances as surveyed by the Industry can be used
to calculate the ‘Maximised Survey-derived Daily Intake’ (MSDI) by assuming that the production figure
only represents 60% of the use in food due to underreporting and that 10% of the total EU population
are consumers (SCF, 1999).
However, the Panel noted that due to year-to-year variability in production volumes, to
uncertainties in the underreporting correction factor and to uncertainties in the percentage of
consumers, the reliability of intake estimates on the basis of the MSDI approach is difficult to assess.
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the
basis of this MSDI-approach, in some cases the regular consumption of products flavoured at use
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In such
cases, the human exposure thresholds below which exposures are not considered to present a safety
concern might be exceeded.
Considering that the MSDI model may underestimate the intake of flavouring substances by certain
groups of consumers, the SCF recommended also taking into account the results of other intake
assessments (SCF, 1999).
One of the alternatives is the ‘Theoretical Added Maximum Daily Intake’ (TAMDI) approach which is
calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable
beverages and foods in general, with exceptional levels for particular foods. This method is regarded
as a conservative estimate of the actual intake in most consumers because it is based on the
assumption that the consumer regularly eats and drinks several food products containing the same
flavouring substance at the upper use level.
One option to modify the TAMDI approach is to base the calculation on normal rather than upper
use levels of the flavouring substances. This modified approach is less conservative (e.g. it may
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels
reported). However, it is considered as a suitable tool to screen and prioritise the flavouring substances
according to the need for refined intake data (EFSA, 2004a).
Figure A.1: Procedure for the safety evaluation of chemically defined flavouring substances
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The method for the modified TAMDI (mTAMDI) calculations is described in Appendix C.
To gather information on the occurrence and levels of a flavouring substance in natural sources, the
Triskelion database is used (available at the following link https://www.vcf-online.nl/VcfHome.cfm/).
b) Genotoxicity
As reflected in the opinion of SCF (1999), the Panel has in its evaluation focused on a possible
genotoxic potential of the flavouring substances or of structurally related substances. Generally,
substances for which the Panel has concluded that there is an indication of genotoxic potential in vitro
will not be evaluated using the EFSA Procedure until further genotoxicity data are provided.
Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated through
the Procedure.
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Appendix B – Specifications for substances in FGE.13Rev3
Table B.1: Summary table on specifications data for flavouring substances in FGE.13Rev3 (for chemical structures, see Appendix D) that are included in
the Union List. Substance [FL-no: 13.155], which is no longer supported by industry and not included in the EU Union list is referenced in the
previous version, FGE.13Rev2 (EFSA CEF Panel, 2011)
Information included in the EU Union list Regulation
(EC) No 1334/2008 as amended
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Information included in the EU Union list Regulation
(EC) No 1334/2008 as amended
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Information included in the EU Union list Regulation
(EC) No 1334/2008 as amended
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Information included in the EU Union list Regulation
(EC) No 1334/2008 as amended
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Information included in the EU Union list Regulation
(EC) No 1334/2008 as amended
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(a): Documentation provided to EFSA (EFFA, 2003, 2004b, Flavour Industry, 2009, 2010) and JECFA (2001c).
(b): At least 95% unless otherwise specified.
(c): Solubility in water, if not otherwise stated.
(d): Solubility in 95% ethanol, if not otherwise stated.
(e): At 1,013.25 hPa, if not otherwise stated.
(f): At 20°C, if not otherwise stated.
(g): At 25°C, if not otherwise stated.
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Appendix C – Exposure estimates
C.1. Normal and maximum use levels
For each of the 18 Food categories (Table C.1) in which the candidate substances are used, Flavour
Industry reports a ‘normal use level’ and a ‘maximum use level’. According to the industry, the ‘normal
use’ is defined as the average of reported usages and ‘maximum use’ is defined as the 95th percentile
of reported usages (EFFA, 2002). The normal and maximum use levels in different food categories
have been extrapolated from figures derived from 12 model flavouring substances (EFFA, 2004a).
The ‘normal and maximum use levels’ have been provided by industry for 25 of the 26 candidate
substances in FGE.13Rev3 (EFFA, 2003, 2004b, 2007, 2017; Flavour Industry, 2009, 2010). For [FL-no:
13.130], information on uses and use levels is missing (Table C.2).
Table C.1: Food categories according to Commission Regulation (EC) No 1565/20003 (Annex III)
Food category Description
01.0 Dairy products, excluding products of category 02.0
02.0 Fats and oils, and fat emulsions (type water-in-oil)
03.0 Edible ices, including sherbet and sorbet
04.1 Processed fruit
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and
legumes), and nuts & seeds
05.0 Confectionery
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses &
legumes, excluding bakery
07.0 Bakery wares
08.0 Meat and meat products, including poultry and game
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms
10.0 Eggs and egg products
11.0 Sweeteners, including honey
12.0 Salts, spices, soups, sauces, salads, protein products etc.
13.0 Foodstuffs intended for particular nutritional uses
14.1 Non-alcoholic (‘soft’) beverages, excl. dairy products
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts
15.0 Ready-to-eat savouries
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) – foods that could not
be placed in categories 01.0–15.0
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Table C.2: Normal and maximum use levels (mg/kg) for the 26 candidate substances in FGE.13Rev3
FL-no
Food categories
Normal use levels (mg/kg)(a),(b)
Maximum use levels (mg/kg)
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FL-no
Food categories
Normal use levels (mg/kg)(a),(b)
Maximum use levels (mg/kg)















































































































































































































































































































































































































(a): ‘Normal use’ is defined as the average of reported usages and ‘maximum use’ is defined as the 95th percentile of reported usages (EFFA, 2002).
(b): ‘Normal and maximum use levels’ provided by industry for 25 of the 26 candidate substances in the present flavouring group (EFFA, 2003, 2004b, 2007, 2017; Flavour Industry, 2009, 2010).
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C.2. mTAMDI calculation
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values is
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may
consume the amount of flavourable foods and beverages listed in Table C.3. These consumption
estimates are then multiplied by the reported use levels in the different food categories and summed up.
The mTAMDI calculations are based on the normal use levels reported by industry. The seven food
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as
outlined in Commission Regulation (EC) No 1565/20003 and reported by the flavour industry in the
following way (see Table C.4):
• Beverages (SCF, 1995) correspond to food category 14.1
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13 and/or
16
• Exception a (SCF, 1995) corresponds to food categories 5 and 11
• Exception b (SCF, 1995) corresponds to food category 15
• Exception c (SCF, 1995) corresponds to food category 14.2
• Exception d (SCF, 1995) corresponds to food category 12
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum.
Table C.3: Estimated amount of flavourable foods, beverages and exceptions assumed to be
consumed per person per day (SCF, 1995)
Class of product category Intake estimate (g/day)
Beverages (non-alcoholic) 324.0
Foods 133.4
Exception a: Candy, confectionery 27.0
Exception b: Condiments, seasonings 20.0
Exception c: Alcoholic beverages 20.0
Exception d: Soups, savouries 20.0
Exception e: Others, e.g. chewing gum E.g. 2.0 (chewing gum)
Table C.4: Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/20003
into the seven SCF food categories used for TAMDI calculation (SCF, 1995)
Food Categories according to Commission Regulation
(EC) No 1565/20003
Distribution of the seven SCF food
categoriesKey
Description Food Beverages Exceptions
01.0 Dairy products, excluding products of category 02.0 Food
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food
03.0 Edible ices, including sherbet and sorbet Food
04.1 Processed fruit Food
04.2 Processed vegetables (incl. mushrooms & fungi, roots &
tubers, pulses and legumes), and nuts & seeds
Food
05.0 Confectionery Exception a
06.0 Cereals and cereal products, incl. flours & starches from roots
& tubers, pulses & legumes, excluding bakery
Food
07.0 Bakery wares Food
08.0 Meat and meat products, including poultry and game Food
09.0 Fish and fish products, including molluscs, crustaceans and
echinoderms
Food
10.0 Eggs and egg products Food
11.0 Sweeteners, including honey Food
12.0 Salts, spices, soups, sauces, salads, protein products, etc. Exception a
Exception d
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Food Categories according to Commission Regulation
(EC) No 1565/20003
Distribution of the seven SCF food
categoriesKey
Description Food Beverages Exceptions
13.0 Foodstuffs intended for particular nutritional uses Food
14.1 Non-alcoholic (‘soft’) beverages, excl. dairy products Beverages
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic
counterparts
Exception c
15.0 Ready-to-eat savouries Exception b
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) –
foods that could not be placed in categories 01.0–15.0
Food
Table C.5: Use of the 25 candidate substances for which use levels have been provided
Food category Description Flavourings used
01.0 Dairy products, excluding products of category 2 All 25
02.0 Fats and oils, and fat emulsions (type water-in-oil) All 25
03.0 Edible ices, including sherbet and sorbet All 25
04.1 Processed fruits All 25 except [FL-no: 13.125 and
13.162]
04.2 Processed vegetables (incl. mushrooms & fungi, roots &
tubers, pulses and legumes), and nuts & seeds
Only [FL-no: 13.199]
05.0 Confectionery All 25
06.0 Cereals and cereal products, incl. flours & starches from
roots & tubers, pulses & legumes, excluding bakery
All 25
07.0 Bakery wares All 25 except [FL-no: 13.136]
08.0 Meat and meat products, including poultry and game All 25
09.0 Fish and fish products, including molluscs, crustaceans
and echinoderms
All 25 except [FL-no: 13.162 and
13.125]
10.0 Eggs and egg products None
11.0 Sweeteners, including honey None
12.0 Salts, spices, soups, sauces, salads, protein products etc. All 25
13.0 Foodstuffs intended for particular nutritional uses All 25 except [FL-no: 13.162 and
13.125]
14.1 Non-alcoholic (‘soft’) beverages, excl. dairy products All 25
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic
counterparts
All 25
15.0 Ready-to-eat savouries All 25 except [FL-no: 13.162]
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat)
– foods that could not be placed in categories 1–15
All 25
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The MSDI and mTAMDI intake estimates for flavouring substances in FGE.13Rev3 are reported in the table below.
Table C.6: Estimated intakes based on the MSDI approach and the mTAMDI approach
FL-no EU Register name MSDI (lg/capita per day) mTAMDI (lg/person per day) Structural class TTC (lg/person per day)
13.122 Ethyl 2-furoate 0.39 3,900 Class II 540
13.130 Furfuryl butyrate 0.24 – Class II 540
13.136 2-Furoic acid 0.013 1,400 Class II 540
13.139 5-Hydroxymethylfurfuraldehyde 0.39 1,600 Class II 540
13.145 Methyl 5-methylfurfuryl sulfide 0.0024 160 Class II 540
13.125 2-Ethyl-5-methylfuran 0.06 540 Class III 90
13.162 2-Octylfuran 0.12 540 Class III 90
13.011 (E)-Ethyl furfuracrylate 0.12 3,900 Class III 90
13.102 Butyl 2-furoate 0.12 3,900 Class III 90
13.108 4,5-Dihydro-3-mercapto-2-methylfuran 37 160 Class III 90
13.113 2,5-Dimethyl-3-(methyldithio)furan 0.0012 160 Class III 90
13.114 2,5-Dimethyl-3-(methylthio)furan 0.0024 160 Class III 90
13.124 Ethyl furfuryl sulfide 0.18 78 Class III 90
13.127 Furfuryl 2-methylbutyrate 0.73 3,900 Class III 90
13.129 Furfuryl but-2(E)-enoate 0.11 3,900 Class III 90
13.132 Furfuryl hexanoate 0.58 3,900 Class III 90
13.133 Furfuryl isobutyrate 0.89 3,900 Class III 90
13.135 1-(2-Furfurylthio)propanone 0.61 780 Class III 90
13.141 Methyl (2-furfurylthio)acetate 0.011 400 Class III 90
13.143 Methyl 3-(furfurylthio)propionate 0.011 420 Class III 90
13.144 Methyl 5-methylfurfuryl disulfide 0.0024 78 Class III 90
13.146 Methyl furfuryl trisulfide 0.0024 160 Class III 90
13.149 5-Methyl-2-furanmethanethiol 0.37 160 Class III 90
13.178 3-[(2-Furanylmethyl)dithio]-2-methyl-furan 0.24 160 Class III 90
13.185 3-[(2-Furanylmethyl)dithio]-2-butanone 0.011 420 Class III 90
13.199 3-[(2-Methyl-3-furyl)thio]-butanal 1.2 49 Class III 90
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Appendix D – Summary of safety evaluations for substances in FGE.13Rev3
Table D.1: Summary of Safety Evaluation Applying the Procedure for substances in FGE.13Rev3 (based on intakes calculated by the MSDI approach)





Outcome on the named compound
and on the material of commerce
EFSA Comments
Main Group I: non-sulfur-containing furan derivatives
Subgroup Ia Structurally related to furfuryl alcohol
13.011 (E)-Ethyl furfuracrylate 0.12 Class III
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13Rev1
The CAS no. should be changed to
53282-12-5
Also evaluated by JECFA as no.
2103
13.102 Butyl 2-furoate 0.12 Class III
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13
13.122 Ethyl 2-furoate 0.39 Class II
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13
13.127 Furfuryl 2-methylbutyrate 0.73 Class III
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13Rev1
13.129 Furfuryl but-2(E)-enoate 0.11 Class III
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13Rev1
The CAS no. should be changed to
136678-63-2 in the Union list
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Outcome on the named compound




Furfuryl butyrate 0.24 Class II
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13Rev2
Also evaluated by JECFA as no.
759
13.132 Furfuryl hexanoate 0.58 Class III
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13
13.133 Furfuryl isobutyrate 0.89 Class III
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13
13.136 2-Furoic acid 0.013 Class II
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13
13.139 5-Hydroxymethylfurfuraldehyde 0.39 Class II
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13Rev2
Subgroup Ib Alkoyl-substituted furans
13.155 2-Methyl-5-propionylfuran 0.011 Class II
No evaluation
No longer supported by Industry
(DG SANCO, 2012)
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Outcome on the named compound
and on the material of commerce
EFSA Comments
Subgroup Ic Alkyl-substituted furans
13.125 2-Ethyl-5-methylfuran 0.06 Class III
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13Rev3
13.162 2-Octylfuran 0.12 Class III
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13Rev3
Main Group II: Sulfur-substituted furan derivatives
Subgroup IIa Sulfides
13.114 2,5-Dimethyl-3-(methylthio)furan 0.0024 Class III
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13
13.124 Ethyl furfuryl sulfide 0.18 Class III
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13
13.135 1-(2-Furfurylthio)propanone 0.61 Class III
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13Rev1
Also evaluated by JECFA as no.
2096
13.141 Methyl (2-furfurylthio)acetate 0.011 Class III
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13Rev1
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Outcome on the named compound
and on the material of commerce
EFSA Comments
13.143 Methyl 3-(furfurylthio)propionate 0.011 Class III
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13Rev1
13.145 Methyl 5-methylfurfuryl sulfide 0.0024 Class II
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13
13.199 3-[(2-Methyl-3-furyl)thio]-butanal 1.2 Class III
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13Rev2
Also evaluated by JECFA as no.
2095
Subgroup IIb Thiols
13.149 5-Methyl-2-furanmethanethiol 0.37 Class III
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes





B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13
Also evaluated by JECFA as no.
2097
Subgroup IIc Disulfides
13.113 2,5-Dimethyl-3-(methyldithio)furan 0.0012 Class III
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13Rev1
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Outcome on the named compound
and on the material of commerce
EFSA Comments
13.144 Methyl 5-methylfurfuryl disulfide 0.0024 Class III
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes





B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13
The chemical name should be
changed to 3-[(2-furanylmethyl)
dithio]-2-methylfuran
Also evaluated by JECFA as no.
1524
13.185 3-[(2-Furfuryl)dithio]-2-butanone 0.011 Class III
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13Rev2




13.146 Methyl furfuryl trisulfide 0.0024 Class III
B3: Intake below threshold, B4:
Adequate NOAEL exists
No safety concern based on intakes
calculated by the MSDI approach
Concluded in FGE.13
(a): EU MSDI: Amount added to food as flavour in (kg/year) 9 10E9/(0.1 9 population in Europe (= 375 9 10E6) 9 0.6 9 365) = lg/capita per day.
(b): Thresholds of concern: Class I = 1,800 lg/person per day, Class II = 540 lg/person per day, Class III = 90 lg/person per day.
(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot.
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Appendix E – Summary of safety evaluations for supporting substances from FGE.67Rev3
Table E.1: Summary of safety evaluations performed by JECFA and EFSA conclusions on these supporting flavouring substances from FGE.67Rev3
JECFA conclusions EFSA conclusions
FL-no
JECFA-no




Outcome on the named
compound based on the
MSDI/SPET(c) approach
Procedural path if different from JECFA, Conclusion
based on the MSDI(d) approach on the named




4: Intake above threshold
5: Adequate NOAEL (25 mg/
kg bw per day) exists
Class III
B3: Intake below threshold
B4: Adequate NOAEL(e) (22.6 mg/kg bw per day) exists




4: Intake above threshold
5: Adequate NOAEL (30 mg/
kg bw per day) exists
Class III
B3: Intake below threshold
B4: Adequate BMDL(e) (8.51 mg/kg bw per day) exists




4: Intake below threshold
Class III
B3: Intake below threshold
B4: Adequate BMDL (8.51 mg/kg bw per day) exists




4: Intake above threshold
5: Adequate NOAEL (30 mg/
kg bw per day) exists
Class III
B3: Intake below threshold
B4: Adequate BMDL (8.51 mg/kg bw per day) exists






4: Intake above threshold
5: Adequate NOAEL (45 mg/
kg bw per day) exists
Class III
B3: Intake below threshold
B4: Adequate BMDL (8.51 mg/kg bw per day) exists
No safety concern concluded in FGE.67Rev3
(a): Thresholds of concern: Class I = 1,800 lg/person per day, Class II = 540 lg/person per day, Class III = 90 lg/person per day.
(b): WHO technical Report Series 1014. Evaluation of certain food additives. Eighty-sixth report of the Joint FAO/WHO Expert Committee on Food Additives.
(c): The highest intake estimate based on either the MSDI or SPET approach will be used in the comparison to the TTC.
(d): EU MSDI: Amount added to food as flavouring in (kg/year) 9 10E9/(0.1 9 population in Europe (= 375 9 10E6) 9 0.6 9 365) = lg/capita per day.
(e): NOAEL or BMDL derived by EFSA see Section 3.4.
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Appendix F – Metabolism
F.1. Introduction
The candidate substances in FGE.13Rev2 are furan derivatives which can be divided into two main
groups (I and II). Ten candidate substances in subgroup Ia are furfuryl alcohol derivatives. In
subgroup Ib, there was only one candidate substance, an alkoyl-substituted furan which was not
supported by Industry and not included in the Union List 4. The two candidate substances in subgroup
Ic are alkyl-substituted furans, without functional groups in the side chains.
The 14 candidate substances in main group II are furan derivatives, containing sulfur substituents
as mono-, di- and tri-sulfides (subgroups IIa, IIc and IId) or free thiol groups (subgroup IIb). The
candidate substance 4,5-dihydro-3-mercapto-2-methylfuran [FL-no: 13.108] in subgroup IIb is a non-
aromatic furan derivative.
The subgrouping has been presented in Table 1 (Section 1.4). Further details on the structural
properties and the metabolism of the substances in the subgroups Ia, Ib, IIa, IIb, IIc and IId are
presented in FGE.13Rev2 (EFSA CEF Panel, 2011) and are not further discussed in this revision of
FGE.13.
In this Annex in FGE.13Rev3, only information on subgroup Ic is reported.
F.2. Subgroup Ic – Alkyl-substituted furans
F.2.1. Hydrolysis of esters
Ester hydrolysis is not an issue for the substances in subgroups Ic.
F.2.2. Absorption, distribution and elimination
Alkylfuran derivatives exhibit rapid uptake, metabolism and excretion. Male Sprague-Dawley rats
administered 100 mg [14C]-2-methylfuran/kg bw in sesame oil via intraperitoneal injection showed
radiolabelled 2-methylfuran [FL-no: 13.030] metabolites in the 12-h urine (Ravindranath and Boyd,
1991). Maximal hepatic radioactivity was detected at 4 h post-administration.
Tissue distribution of 50–200 mg [14C]-2-methylfuran/kg bw over 24 h showed the presence of
radiolabel from greatest to least as follows: liver > kidney > lung > blood. The maximal amount of
radiolabel was detected in the liver at 8 h post administration, followed by a steady decline up to 24 h
(Ravindranath et al., 1986).
Based on these data, the members of this group of furan-substituted aliphatic hydrocarbons,
alcohols, aldehydes, ketones, carboxylic acids and related esters are anticipated to be rapidly
absorbed, distributed through key organs involved in metabolic processes and then eliminated,
primarily in the urine.
F.2.3. Biotransformation
No data were available on the candidate substances in subgroup Ic. However, some data on
supporting substances have been summarised by the JECFA (JECFA, 2009a). The following text is
based on this JECFA evaluation in which some modifications have been included after consultation of
the original publications.
For the candidate substances in subgroup Ic, it is of relevance that alkyl-substituted furan
derivatives may undergo cytochrome P450-mediated side-chain oxidation to yield an alcohol functional
group located at the position bonded directly to the furan ring. The resulting secondary alcohol may be
excreted in the urine primarily as the glucuronic acid or sulfate conjugate, or it may be converted to
the corresponding ketone, which may also be excreted in the urine. This kind of side-chain oxidation,
preferably at the C1’ position of furan, is similar to that observed with other alkyl-substituted
heterocyclic derivatives (e.g. pyridine derivatives and indoles) (Hawksworth and Scheline, 1975;
Thornton-Manning et al., 1993). It is noted that the resulting secondary furyl alcohol forms an a,b-
unsaturated carbonyl system with the double bonds in the furan ring. In addition to side-chain
oxidation, the furan ring can undergo cytochrome P450-induced oxidation followed by opening of the
ring to yield reactive 2-enal or 2-enedial intermediates. It is not entirely clear if in these reactions also
epoxide intermediates are involved, but if so, they have to be very unstable. The 2-enedial
intermediates have been shown to form protein and DNA adducts. They also may conjugate readily
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with GSH, but as their GSH conjugates are unstable, this conjugation offers no protection. However,
conjugation with cysteine results in a stable non-reactive product (Ravindranath et al., 1983, 1984,
1986; Ravindranath and Boyd, 1985, 1991).
Initial in vitro experiments in rat microsomal preparations suggested that high concentrations of
alkyl-substituted furans are partly metabolised to reactive acetylacrolein-type intermediates
(Ravindranath et al., 1983, 1984). Acetylacrolein is a potent microsomal mixed-function oxidase
inhibitor that has been reported to bind covalently and irreversibly to the oxidising enzyme, thus
inactivating it (Ravindranath and Boyd, 1985).
Acetylacrolein (= 4-oxo-pent-2-enal) is a potent microsomal mixed-function oxidase inhibitor which
has been reported to bind covalently and irreversibly to the oxidising enzyme, thus deactivating it
(Ravindranath and Boyd, 1985). Significant protein binding (> 55 nmol/mg protein) was reported when
10 mmol/L of [2-14C]-methylfuran were incubated with rat hepatic microsomes in the presence of
NADPH and oxygen. In the absence of oxygen or NADPH, little binding was observed (< 2 nmol/mg
protein). These findings suggest that NADPH-dependent oxidation of 2-methylfuran is a prerequisite
for protein binding. Increased protein binding (> 80 nmol/mg protein) was also reported when
Sprague-Dawley rats were pre-treated with phenobarbital, a cytochrome P450 inducer, while
decreased or no protein binding was observed in the presence of piperonyl butoxide or N-octyl
imidazole, both of which inhibit cytochrome P450. The Vmax and Km for 2-methylfuran metabolism in
phenobarbital pre-treated rats were 0.81 lmol/2 mg microsomal protein per min and 0.463 mmol/l,
respectively, and those in rats without phenobarbital pre-treatment were 0.53 lmol/2 mg microsomal
protein per min and 1.417 mmol/L, respectively. These values suggest that 2-methylfuran undergoes
cytochrome P450-mediated oxidation to yield a reactive metabolite (i.e. acetylacrolein) which binds
covalently to protein (Ravindranath and Boyd, 1985). With 3-methylfuran, a similar ring opening
product (3-methyl-but-2-enedial) has been found (Ravindranath et al., 1983, 1984).
In the same study (Ravindranath and Boyd, 1985), when acetylacrolein at 0.25 mmol/L (24.5 lg/mL)
was added to the incubation mixture, microsomal metabolism of 2-methylfuran was almost completely
inhibited (covalent binding was 1.5% of the control incubation). At a concentration of 0.5 mmol
acetylacrolein/L (49.1 lg/mL), no metabolism of 2-methylfuran was detectable, suggesting that
acetylacrolein inhibits cytochrome P450-mediated oxidation, probably through direct covalent binding
with the enzyme. Thus, 2-methylfuran is a suicide substrate for this enzyme. Conjugation of the reactive
metabolite with sulfhydryl trapping agents, including cysteine (10 mmol/L) and GSH (10 mmol/L),
showed a marked decrease in microsomal protein binding, suggesting that sulfhydryl conjugation plays a
role in the detoxication of acetylacrolein. Cysteine was the better trapping agent for the prevention of
microsomal protein binding when compared with GSH, semicarbazide, lysine or N-acetylcysteine. The
authors postulated that cysteine forms a stable cyclic conjugate with a, b-unsaturated aldehydes,
whereas the ability of GSH to form stable conjugates with a, b-unsaturated aldehydes varies (Esterbauer
et al., 1975, 1976; Ravindranath and Boyd, 1985).
Other in vitro experiments support the conclusion that cytochrome P450-mediated oxidation of 2-
methyl-furan is directly related to its toxicity. This was studied in hepatocytes isolated from adult male
Wistar rats that were untreated or treated with phenobarbitone (0.1% in drinking water for 5 days) or
b-naphthoflavone (80 mg/kg bw by intraperitoneal injection daily for 3 days). The cultured
hepatocytes were incubated with 2-methylfuran at 0, 100, 300, 600 or 1,000 lmol/L (0, 8.2, 24.6,
49.3 and 82.1 lg/mL, respectively) for 24 h. The median lethal concentrations (LC50 values) for
untreated, phenobarbitone-treated or b-naphthoflavone-treated hepatocytes were 794, 34 and 57
lmol/L (65.2, 2.8 and 4.7 lg/mL), respectively, indicating that enzyme induction increased the toxicity
of 2-methylfuran (Hammond and Fry, 1991).
Male Sprague-Dawley rats (150–200 g) were administered a single dose of 50, 100, 200 or 400 mg
2-methylfuran/kg bw in sesame oil by intraperitoneal injection and were sacrificed 24 h later. The
50 mg/kg bw group did not show any evidence of liver necrosis, but they exhibited endothelial injury,
with blebbing of the endothelium into the vascular lumen of the central veins. Animals given 100, 200
or 400 mg 2-methylfuran/kg bw showed a dose-related increase in the severity of hepatocellular injury
(e.g. eosinophilic cytoplasm, vacuolation), centrilobular necrosis and necrosis and sloughing of the
bronchiolar epithelium, which, at the high dose, resulted in complete obliteration of numerous
respiratory and terminal bronchioles. Dose-related increases in serum glutamic pyruvic transaminase
(GPT) were observed up to 200 mg 2-methylfuran/kg bw; however, the levels of serum GPT in the
animals given 50 mg 2-methylfuran/kg bw were not significantly higher than those of the control rats.
Free GSH levels in the liver, lungs and kidneys, investigated over a period of 0.5–36 h after
administration of 100 mg 2-methylfuran/kg bw, were initially decreased (67.5% of control in the liver
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and 87% of control in the kidneys at 0.5 h), but then reached or exceeded control levels within 8–24 h
(137% of control in the kidneys and 130% of control in the lungs at 12 h). Tissue distribution and
covalent binding studies were conducted over a period of 0.5–24 h after an intraperitoneal dose of
100 mg [14C]-2-methylfuran/kg bw. The radiolabelled [14C]-2-methylfuran covalently bound to protein
was detected at the highest concentration in the liver, followed by the kidney, lung and blood. Liver
and kidney DNA also showed covalent binding of 14C label. Maximal covalent binding to DNA was
observed in the liver at 1 h and in the kidney at 4 h. With phenobarbital pretreatment, a twofold
increase in binding in the liver was observed. Conversely, N-octylimidazole pretreatment decreased the
level of covalent binding of the 14C label to proteins and DNA in the liver, lung and kidney. Increased
and decreased protein binding and hepatotoxicity measured as serum GPT levels were observed in rats
pretreated with phenobarbital and N-octylimidazole, respectively. 3-Methylcholanthrene or piperonyl
butoxide pretreatment did not affect either covalent binding or hepatotoxicity. These results provide
evidence that bioactivation of 2-methylfuran by a CYP system is a prerequisite for tissue necrosis in
rats (Ravindranath et al., 1986).
In a study examining GSH and cysteine conjugation on the toxic potential of 2-methylfuran, male
Sprague-Dawley rats were treated subcutaneously with a 900 mg/kg bw dose of buthionine
sulfoximine 1.5 h prior to intraperitoneal administration of 100 mg [14C]2-methylfuran/kg bw prepared
in sesame oil. Marked decreases in covalent DNA and protein binding in the liver and reduced
hepatotoxicity, as indicated by lower serum GPT levels, were observed. Buthionine sulfoximine
treatment revealed a transient increase in plasma cysteine levels, concurrent with a decrease in GSH
levels. However, administration of 100 mg 2-methylfuran/kg bw 1.5 h after buthionine sulfoximine
administration significantly reduced plasma cysteine levels and increased (20%) urinary elimination of
2-methylfuran-labelled metabolites compared with the control group ([14C]-2-methylfuran only).
Subcutaneous pretreatment with diethylmaleate, a depletor of liver GSH, at 0.4 ml/kg bw increased
binding to liver proteins and increased hepatotoxicity, as indicated by a rise in serum GPT levels
compared with rats that received only 2-methylfuran. Subcutaneous pretreatment of rats with GSH
synthesis promoter L-2-oxothiazolidine-4-carboxylate at a dose of 1,000 mg/kg bw resulted in a
marked increase of covalent protein binding in the liver and potentiated hepatotoxicity (increased
serum GPT levels compared with rats that received only 2-methyl-furan). When rats were pretreated
with both buthionine sulfoximine and L-2-oxothiazolidine-4-carboxylate, a marked decrease in covalent
protein binding in the liver and hepatotoxicity, as indicated by a reduction in serum GPT levels, was
observed. No unchanged 2-methylfuran was observed in the urine, indicating that pretreatment did
not inhibit metabolic processes (Ravindranath and Boyd, 1991). The authors proposed that buthionine
sulfoximine pretreatment indirectly aids in the detoxication of 2-methylfuran through a reduction of
GSH supply and an increase in the availability of cysteine, which forms a more stable conjugate with
acetylacrolein than GSH.
Adult male Swiss albino mice (10–15 per group) were administered 2-ethylfuran (commercial grade,
FL-no: 13.092) at 200 mg/kg bw in sesame oil via intraperitoneal injection with or without
phenobarbital, piperonyl butoxide or cobalt(II) chloride pretreatment. The mortality rates were 1/10,
2/10, 3/15 and 2/11 for the untreated, phenobarbital pretreatment, piperonyl butoxide pretreatment
and cobalt(II) chloride pretreatment groups, respectively. 2-Ethylfuran produced a moderate necrosis
of the liver and mild to moderate necrosis of the kidneys. The kidney necrosis was described as a
coagulative lesion of the proximal convoluted tubules of the outer cortex, without damage to the
glomerular or medullary cells. Piperonyl butoxide and cobalt(II) chloride decreased the severity of
necrosis in the liver and kidney (McMurtry and Mitchell, 1977).
In the same study, mice were injected intraperitoneally with 70 mg 2-acetylfuran [FL-no: 13.054]
(commercial grade)/kg bw in 0.9% sodium chloride, with and without phenobarbital pretreatment, and
80 mg 2-acetylfuran/kg bw, with and without cobalt(II) chloride pretreatment. The mortality rates
were 1/12, 0/12, 0/12 and 0/12 for the 70 mg 2-acetylfuran/kg bw, 70 mg 2-acetylfuran/kg bw plus
phenobarbital, 80 mg 2-acetylfuran/kg bw, and 80 mg 2-acetylfuran/kg bw plus cobalt(II) chloride
treatment groups, respectively. Mice treated with 2-acetylfuran showed no evidence of toxicity in the
kidneys. Hepatic necrosis, described as midzonal-centrilobular necrosis of the parenchymal
hepatocytes, was mild in severity with cobalt(II) chloride pretreatment, showing a marked decrease in
the incidence and severity of necrosis (McMurtry and Mitchell, 1977).
Ten male ICR mice were injected intraperitoneally with 2-ethylfuran (analytical reagent grade) at
2.6 mmol/kg bw (250 mg/kg bw) in sesame oil. Histopathology of tissues collected 24 h later revealed
extensive proximal tubular necrosis of the kidneys and focal hydroptic degeneration of the liver.
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Significant increases in the plasma urea nitrogen level (approximately five times control level) and GPT
level were reported (Wiley et al., 1984).
Severe bronchiolar necrosis was reported when 2-ethylfuran (2.6 mmol/kg bw or 250 mg/kg bw)
in sesame oil was administered by intraperitoneal injection to male ICR mice. Administration of 1.56
mmol 2-ethylfuran/kg bw (150 mg/kg bw) via intraperitoneal injection to five male ICR mice showed
approximately a doubling, compared with control values, of the amount of [14C]-thymidine
incorporation into pulmonary DNA measured at 3 days after dosing, which indicates increased cell
replication and lung repair (Gammal et al., 1984).
In a study of the tumour-inhibiting properties of 2-heptylfuran [FL-no: 13.069], increased cytosolic
glutathione S-transferase activity was observed in tissue preparations of the liver, forestomach and
small bowel mucosa isolated from 7-week-old female A/J mice (five mice per group) that received
doses of 12, 25, 50 or 80 lmol of 2-heptylfuran dissolved in cottonseed oil via gavage every other day
for a total of three doses. A 50 lmol dose of 2-heptylfuran showed a significant increase in acid-
soluble sulfhydryl levels, which is a good measure of GSH content in tissues, in all four tissue types
(liver, small bowel mucosa, forestomach and lung) when compared with controls. At lower dose levels,
the increases became inconsistent. At the highest dose level, the increase was lower than at 50 lmol
probably because of the toxicity of the substance (Lam and Zheng, 1992).
In summary, 2-alkyl-substituted furans can be metabolised by side-chain oxidation to initially yield
the 1’-alcohol derivative, which can be either conjugated and excreted or oxidised to the
corresponding (a,b,-unsaturated) ketone. The conversion to the ketone is anticipated to be reversible,
in which case the ketones are reduced to the corresponding alcohols and excreted mainly in the urine.
In a second pathway, the furan ring can be oxidised and may undergo rapid ring opening to yield
reactive 2-ene-1,4-dicarbonyls (e.g. acetylacrolein) possibly through an unstable epoxide intermediate.
These reactive 2-ene-1,4-dicarbonyls can be conjugated with available sulfhydryl trapping agents, such
as GSH and cysteine, or can be covalently bound to proteins and DNA.
Much less information is available on the metabolism of dialkylfurans, of which the candidate
substance [FL-no: 13.125] is an example. For 2,5-dimethylfuran, the formation of the reactive
metabolite hex-3-ene-2,5-dione has been postulated, based on studies with dimethylfuran in
microsomal incubates, using trapping agents (Wang et al., 2015). It could be demonstrated that this
intermediate showed reactivity towards amino- or thiol-moieties in proteins in these in vitro systems.
In protein-digests of various tissues (liver, heart, lung, kidney, serum), dimethylfuran-derived adducts
were detected after intraperitoneal administration of 2,5-dimethylfuran to mice.
F.3. Summary
The mono-alkyl furans from subgroup Ic, such as the candidate substance 2-octylfuran [FL-no:
13.162], may undergo oxidation (possibly epoxidation of the unsubstituted double bond) and
rearrangement to an oxo-aldehyde (a ring-opening product). For several 2-alkyl-substituted furans
reactivity of these oxo-aldehydes towards proteins and DNA has been demonstrated, resulting in
toxicity to liver and kidneys. In addition, oxidation of the C1’-carbon of the alkyl substituent may result
in the formation of an a,b-unsaturated ketone, for which genotoxicity might be anticipated. For 2,5-
dimethylfuran, the formation of hex-3-ene-2,5-dione has been postulated.
F.4. Conclusion
For candidate substances in subgroup Ic, oxidation and opening of the furan ring, which results in
the formation of reactive and toxic metabolites can be anticipated. It cannot be concluded that these
substances are metabolised only into innocuous products.
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Appendix G – Genotoxicity studies on supporting substances considered in FGE.13Rev2 and in FGE.67Rev2













Reverse mutation S. Typhimurium TA98 and
TA100
0.165, 0.330, 0.495 or 0.660 lmol/plate
(13.5, 27.1, 40.6 or 54.2 lg/plate)(a)
Negative(b) Shinohara et al. (1986)
Reverse mutation S. Typhimurium TA98,
TA100, TA102 and TA1535
Up to 10,000 lg/plate Negative(b),(c),(d) Zeiger et al. (1992)
Reverse mutation S. Typhimurium TA97 and
TA104
Up to 10,000 lg/plate Equivocal(b),(c),(d) Zeiger et al. (1992)
Reverse mutation S. Typhimurium TA98, TA100
and TA102
11 nmol/plate to 1.1 mmol/plate
(0.9–90,310 lg/plate)(a)
Negative(b) Aeschbacher et al. (1989)
DNA damage B. subtilis H17 (rec+) and
M45 (rec)
0.16, 16 or 1,600 lg/disc Negative
Positive(b),(e)
Shinohara et al. (1986)
Chromosomal
aberration




Reverse mutation S. Typhimurium TA98 and
TA100
0.165, 0.330, 0.495 or 0.660 lmol/plate
(13.5, 27.1, 40.6 or 54.2 lg/plate)(g)
Negative(b) Shinohara et al. (1986)
Reverse mutation S. Typhimurium TA98 and
TA100
Not specified Negative(b) Lee et al. (1994)
Reverse mutation S. Typhimurium TA97, TA98,
TA100 and TA1535
Up to 3,333 lg/plate Negative(b),(c),(d) Zeiger et al. (1992)
DNA damage B. subtilis H17 (rec+) and
M45 (rec)
190, 1,900 or 9,500 lg/disc Negative
Positive(b),(h)
Shinohara et al. (1986)
Chromosomal
aberration
Chinese hamster V79 cells 1 mmol/L (96.13 lg/mL)(g) Negative Ochi and Ohsawa (1985)
Chromosomal
aberration






Reverse mutation S. Typhimurium TA98,
TA100, TA1535 and TA1537
3.2, 16, 80, 400 or 2,000 lg/plate Negative(b) Asquith (1989)
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Reverse mutation S. Typhimurium TA98 and
TA100
0.165, 0.330, 0.495 or 0.660 lmol/plate
(13.5, 27.1, 40.6 or 54.2 lg/plate)(i)
Negative
Positive(b),(j)
Shinohara et al. (1986)
DNA damage E. coli PQ37 (SOS
chromotest)
Not specified Slightly positive(i) Eder et al. (1993)
DNA damage B. subtilis H17 (rec+) and
M45 (rec)
550, 5,500 or 55,000 lg/disc Negative
Positive(b),(k)
Shinohara et al. (1986)
Chromosomal
aberration
CHO cells 0–112.6 mmol/L (0–13,220 lg/mL)(i) Positive(b),(l),(m) Stich et al. (1981)









Mouse bone marrow cells
and spermatocytes
1,000, 2,000 or 4,000 mg/kg (100, 200 or
400 mg/kg bw per day)(n)






Mouse bone marrow 1,000, 2,000 or 3,000 mg/L (20, 40 or 60
mg/kg bw)(o)
Positive(p),(q) Sujatha et al. (1993)
Chromosomal
aberration
Mouse spermatocytes 1,000, 2,000 or 3,000 mg/L (20, 40 or 60
mg/kg bw)(o)
Negative(r) Sujatha et al. (1993)
SCE Mouse bone marrow 1,000, 2,000 or 3,000 mg/L (20, 40 or 60
mg/kg bw)(o)
Positive Sujatha (2007)
UDS Rat liver 7 or 21 mg/kg bw Negative Durward (2007b)
CHO: Chinese hamster ovary; SCE, sister chromatid exchange; UDS, unscheduled DNA synthesis.
(a): Calculated using relative molecular mass of 2-methylfuran = 82.1.
(b): With and without metabolic activation.
(c): Preincubation method.
(d): Occasional incidences of slight to complete clearing of the background lawn at the higher concentrations.
(e): Negative at all concentrations with metabolic activation; positive without metabolic activation.
(f): Clastogenic activity decreased with metabolic activation (statistical significance of results was not specified).
(g): Calculated using relative molecular mass of 2,5-dimethylfuran = 96.13.
(h): Positive at every concentration without metabolic activation; with metabolic activation, negative at 190 lg/disc, but positive at higher concentrations.
(i): Calculated using relative molecular mass of 2-furyl methyl ketone = 110.11.
(j): Positive only in strain TA98 with an increase in the presence of metabolic activation.
(k): Negative at 550 lg/disc; positive at 5,500 and 55,000 lg/disc (with and without metabolic activation).
(l): Cytotoxicity was observed at 12 398 lg/mL (112.6 mmol/L) in the presence of metabolic activation.
(m): Clastogenic activity increased with metabolic activation (statistical significance of results was not specified).
(n): Mice received 2-methylfuran in the diet for 5 consecutive days at 24-h intervals.
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(o): Two experimental protocols were utilised. In one experiment, animals received single oral dose administrations of the test compound. In the other experiment, the test compound was orally
administered once per day at the same concentrations as in the single-dose study for 5 consecutive days with 24-h intervals between doses.
(p): No effects observed at 20 mg/kg bw dose level and only mild, but significant (p < 0.05) effects seen at higher concentrations in bone marrow cells.
(q): Chromosomal aberrations were observed in the presence of significant mitodepression.
(r): A single statistically significant occurrence of increased chromosomal aberrations observed 3 weeks following a single dose administration in the 60 mg/kg bw test group; statistically significant
increases in polyploidy and XY univalents observed at weeks 3 and 4 at 60 mg/kg bw in multiple dose-treated rats.
(s): Substance deleted from the Union list. Commission Regulation (EU) No 246/2014 of 13 March 2014 amending Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the
Council as regards removal from the Union list of certain flavouring substances. OJ L 74, 14.3.2014, p. 58–60.
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Appendix H – Genotoxicity studies on supporting substances from FGE.67Rev3
No genotoxicity studies are available on candidate substances from subgroup Ic. Available studies on the supporting substance 2-pentylfuran [FL-no:
13.059] and on 2-acetylfuran [FL-no: 13.054] are presented in Tables H.1 and H.2.




Test system Test object





Micronucleus assay Human peripheral
blood lymphocytes
From 34.7 to 1,111(a),(b),(c) Negative Charles River (2020a) Reliable without restrictions.
Study performed in compliance
with OECD TG 487 and GLP
2-pentylfuran
[13.059]
Micronucleus assay Human peripheral
blood lymphocytes
From 54.5 to 100.8(a),(b)
From 51.4 to 91.1(c)
Negative Charles River (2020b) Reliable without restrictions.
Study performed in compliance
with OECD TG 487 and GLP
(a): Without S9 metabolic activation, 4 + 20 h treatment.
(b): With S9 metabolic activation, 4 + 20 h treatment.
(c): Without S9 metabolic activation, 24 h treatment.
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Gavage 0, 15, 30 and 60 Negative Covance (2016) Reliable with restrictions (no clear
evidence of bone marrow exposure).
Study performed in compliance with GLP
and according to OECD TG 474, but
positive control was not included
Gene mutation
assay in liver and
duodenum
Negative Reliable without restrictions. Study
performed in compliance with GLP and
according to OECD TG 488
2-pentylfuran
[13.059]









The study aimed at comparing furan and
2-pentylfuran. Liver was sampled 3h
after treatment
762 Negative both with
and without proteinase
K














Gavage 42.5, 85, 170(a) Negative Covance (2014) Reliable with restrictions (no clear
evidence of bone marrow exposure).
Study performed in compliance with GLP
and according to OECD TG 474
Comet assay (liver) Negative Reliable without restrictions. The study
was performed in compliance with
recommendations of the Comet and
IWGT workshop, Japanese Center for the
Validation of Alternative Methods
(JaCVAM) and current literature
M: male.
(a): Administered via gavage in three doses at times 0, 24 and 45 h with sacrifice and harvest at 48 h.
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Appendix I – Toxicity studies on supporting substances from FGE.67Rev3
No toxicity studies are available on candidate substances from subgroup Ic. Available studies on the supporting substance 2-pentylfuran [FL-no: 13.059]
and on 2-acetylfuran [FL-no: 13.054] are presented in Table I.1.
















Rat; M & F; 32 rats for
control and lowest
dose; 12 rats for the
mid dose; 10 rats for
the highest dose




0, 5, 25 (nominal,
equal to 22.6 in males
and 27 in females)
90 22.6 Study conducted according
to OECD TG 408 and GLP
2-pentylfuran
[13.059]
Mice; M & F; 5
animals/group









Rats; M & F; 23
animals/group
Diet 0, 25.6 90 – Gulf South Research
Institute (1971b)
Rat; M & F 5/sex/dose
level
Diet 0, 100, 250 and 500 14 – Product Safety Labs
(2016)




0, 30, 100 and 150 90 8.51 Product Safety Labs
(2017)
Study conducted according
to OECD TG 408 and GLP.
Value 8.51 is BMDL22. The
study authors proposed a
NOAEL of 30 mg/kg bw per
day
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